valproic acid has been researched along with Complications, Pregnancy in 319 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This paper aims to undertake a comprehensive review regarding the possible risks of four classical (phenytoin, carbamazepine, phenobarbital, and valproate) and two newer (lamotrigine and levetiracetam) AEDs during pregnancy." | 9.12 | Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications. ( Demir, O; Kaplan, YC, 2021) |
| "In eight women treated with lamotrigine monotherapy, the lamotrigine dose/plasma concentration (D/C) ratio increased by 295% from baseline outside pregnancy to midgestation, whereas in six women treated with lamotrigine in combination with valproate, the increase was only 60%." | 9.12 | Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. ( Luef, G; Ohman, I; Pittschieler, S; Sabers, A; Tomson, T, 2006) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 8.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| "The use of valproic acid in the first trimester of pregnancy is associated with an increased risk of spina bifida, but data on the risks of other congenital malformations are limited." | 8.86 | Valproic acid monotherapy in pregnancy and major congenital malformations. ( Barisic, I; de Jong-van den Berg, LT; Dolk, H; Garne, E; Jentink, J; Loane, MA; Morris, JK, 2010) |
| " However, a particular association of valproate and carbamazepine with neural tube defects (NTDs)--specifically, with spina bifida aperta (SB)--has been identified." | 8.82 | Management issues for women with epilepsy: neural tube defects and folic acid supplementation. ( Yerby, MS, 2003) |
| "Administration of the antiepileptic drug valproic acid (VPA) during early pregnancy can result in a 1-2% incidence of spina bifida aperta, a closure defect of the posterior neural tube in the human." | 8.78 | Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. ( Ehlers, K; Hauck, RS; Nau, H, 1991) |
| "This study was carried out to determine changes over time in use of folic acid, anti-epileptic drugs (AED), seizures during pregnancy and malformation rate over two decades in women with epilepsy enrolled in the Kerala registry of Epilepsy and Pregnancy (KREP)." | 7.96 | Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. ( A S, R; Baishya, J; Jose, M; Keni, RR; Sankara Sarma, P; Thomas, SV, 2020) |
| "The study was performed using a rodent model of autism by exposing rat fetuses to valproic acid (VPA) on the 12." | 7.85 | Postnatal treatment using curcumin supplements to amend the damage in VPA-induced rodent models of autism. ( Al-Askar, M; Al-Ayadhi, L; Bhat, RS; El-Ansary, A; Selim, M, 2017) |
| "Based on data from the EURAP observational International registry of antiepileptic drugs (AEDs) and pregnancy, we assessed changes in seizure control and subsequent AED changes in women who underwent attempts to withdraw valproic acid (VPA) during the first trimester of pregnancy." | 7.83 | Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2016) |
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 7.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| "Health care providers reported lamotrigine exposure during pregnancy, and subsequent outcomes, on a voluntary basis." | 7.77 | Final results from 18 years of the International Lamotrigine Pregnancy Registry. ( Cunnington, MC; Ferber, S; Messenheimer, JA; Tennis, P; Weil, JG; Yerby, M, 2011) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 7.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| " In utero, exposure to valproic acid (VPA) and phenytoin (PH) may cause congenital malformations and also withdrawal symptoms such as irritability, jitteriness and symptoms of hypoglycemia." | 7.76 | Neonatal episodic hypoglycemia: a finding of valproic acid withdrawal. ( Akçakuş, M; Akın, MA; Çoban, D; Güneş, T; Kurtoğlu, S, 2010) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 7.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| "Neural tube defects (NTDs) are the most common of the major anomalies associated with in utero exposure to valproic acid." | 7.70 | Safe use of valproic acid during pregnancy. ( Kennedy, D; Koren, G, 1999) |
| "The authors studied antipyrine disposition before and after delivery in 4 epileptic women whose anticonvulsant plasma level per dosage ratio was lowered during pregnancy, and compared the results to those found in nonpregnant women undergoing antiepileptic treatment (N = 6) and healthy women (N = 6)." | 7.66 | Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ( Chiba, K; Ishizaki, T; Nakazawa, Y; Tabuchi, T; Wagatsuma, T, 1982) |
| "When treatment with valproic acid is the most appropriate treatment to achieve optimal seizure control, a number of measures can be implemented to minimise risk to the fetus." | 6.43 | Valproic acid in epilepsy : pregnancy-related issues. ( Genton, P; Semah, F; Trinka, E, 2006) |
| "Focal epilepsy was diagnosed in 244 (69." | 5.51 | Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study. ( Bosak, M; Słowik, A; Turaj, W, 2019) |
| " This paper aims to undertake a comprehensive review regarding the possible risks of four classical (phenytoin, carbamazepine, phenobarbital, and valproate) and two newer (lamotrigine and levetiracetam) AEDs during pregnancy." | 5.12 | Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications. ( Demir, O; Kaplan, YC, 2021) |
| "In eight women treated with lamotrigine monotherapy, the lamotrigine dose/plasma concentration (D/C) ratio increased by 295% from baseline outside pregnancy to midgestation, whereas in six women treated with lamotrigine in combination with valproate, the increase was only 60%." | 5.12 | Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. ( Luef, G; Ohman, I; Pittschieler, S; Sabers, A; Tomson, T, 2006) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 4.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| " Oxcarbazepine and lamotrigine were associated with increased occurrence of autism." | 4.95 | Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. ( Cogo, E; D'Souza, J; Finkelstein, Y; Hemmelgarn, BR; Hutton, B; Kealey, R; MacDonald, H; Reynen, E; Rios, P; Soobiah, C; Straus, SE; Thavorn, K; Tricco, AC; Veroniki, AA; Yazdi, F, 2017) |
| "Valproic acid (VPA) use during pregnancy increases fetal risk of major congenital malformations and cognitive impairment." | 4.93 | Guideline adherence for mentally ill reproductive-aged women on treatment with valproic acid: a retrospective chart review. ( Gotlib, D; Kurlander, J; Muzik, M; Perelstein, E; Riba, M; Zivin, K, 2016) |
| "The developmental quotient (DQ) was lower in children exposed to carbamazepine (CBZ) (n = 50) than in children born to women without epilepsy (n = 79); mean difference (MD) of -5." | 4.90 | Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. ( Adab, N; Bromley, R; Greenhalgh, J; Marson, AG; McKay, AJ; Sanniti, A; Tudur Smith, C; Weston, J, 2014) |
| "The use of valproic acid in the first trimester of pregnancy is associated with an increased risk of spina bifida, but data on the risks of other congenital malformations are limited." | 4.86 | Valproic acid monotherapy in pregnancy and major congenital malformations. ( Barisic, I; de Jong-van den Berg, LT; Dolk, H; Garne, E; Jentink, J; Loane, MA; Morris, JK, 2010) |
| "Valproic acid (2-n-propylpentanoic acid, VPA) is well-established as a mood-stabilizer for bipolar disorder, in addition to its application as a treatment in neurological disorders such as epilepsy, migraine headaches, and chronic neuropathic pain." | 4.84 | Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. ( Rasgon, NL; Reynolds, MF; Sisk, EC, 2007) |
| " However, a particular association of valproate and carbamazepine with neural tube defects (NTDs)--specifically, with spina bifida aperta (SB)--has been identified." | 4.82 | Management issues for women with epilepsy: neural tube defects and folic acid supplementation. ( Yerby, MS, 2003) |
| "Administration of the antiepileptic drug valproic acid (VPA) during early pregnancy can result in a 1-2% incidence of spina bifida aperta, a closure defect of the posterior neural tube in the human." | 4.78 | Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. ( Ehlers, K; Hauck, RS; Nau, H, 1991) |
| "Valproic acid use during pregnancy results in an absolute risk for spina bifida of 1-2%." | 4.77 | Teratogen update: valproic acid. ( Lammer, EJ; Oakley, GP; Sever, LE, 1987) |
| "05) of an increased hazard of fetal malformation associated with exposure to valproate, carbamazepine, topiramate, zonisamide, and with conception after assisted fertilization, but a reduced hazard in the offspring of women who continued to smoke during pregnancy." | 4.31 | Specific fetal malformations following intrauterine exposure to antiseizure medication. ( Eadie, M; Graham, J; Hitchcock, A; Lander, C; O'Brien, T; Perucca, P; Vajda, F, 2023) |
| "Use of valproate and carbamazepine decreased progressively, use of lamotrigine remained relatively static, and the use of levetiracetam increased progressively, whereas the use of topiramate first increased and then fell again, associated with a temporary increase in malformation-associated pregnancy rate." | 4.31 | Changes over 24 years in a pregnancy register - Teratogenicity and epileptic seizure control. ( Eadie, M; Graham, J; Hitchcock, A; Lander, C; O'Brien, T; Perucca, P; Vajda, F, 2023) |
| " In our case series, lamotrigine proved to be less effective and less controllable than other drugs during pregnancy." | 4.12 | [Women with epilepsy before and during pregnancy: a case series of outpatient counseling in a tertiary epilepsy center]. ( Bien, CG; Hagemann, A; Knaak, N; Müffelmann, B, 2022) |
| " In most Australian women starting therapy for epilepsy initiating treatment with levetiracetam monotherapy may offer the best chance of such a desirable outcome to a future pregnancy, yet to be confirmed." | 4.12 | Achieving neurologically desirable outcomes to pregnancy in women with epilepsy. ( Eadie, MJ; Graham, JE; Hitchcock, AE; Lander, CM; O'Brien, TJ; Perucca, P; Vajda, FJE, 2022) |
| "Statistical analysis of data from the Raoul Wallenberg Australian Register of Antiepileptic Drugs in Pregnancy involving 2104 folic acid-treated pregnancies in women with epilepsy." | 4.02 | Folic acid dose, valproate, and fetal malformations. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Perucca, P; Vajda, FJE, 2021) |
| "This study was carried out to determine changes over time in use of folic acid, anti-epileptic drugs (AED), seizures during pregnancy and malformation rate over two decades in women with epilepsy enrolled in the Kerala registry of Epilepsy and Pregnancy (KREP)." | 3.96 | Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. ( A S, R; Baishya, J; Jose, M; Keni, RR; Sankara Sarma, P; Thomas, SV, 2020) |
| "Valproic acid (VPA) is currently one of the four most often prescribed antiepileptic drugs (AEDs) in pregnancy." | 3.91 | Valproic acid concentrations in nursing mothers, mature milk, and breastfed infants in monotherapy and combination therapy. ( Brozmanova, H; Grundmann, M; Kacirova, I, 2019) |
| " This limitation and high risks of neural tube and other major teratogenic effects, especially of valproate, indicate the need for great caution in the use of valproate and carbamazepine to treat bipolar disorder in women of child-bearing age." | 3.88 | Mood-Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary. ( Baldessarini, RJ; Patel, N; Viguera, AC, 2018) |
| "The study was performed using a rodent model of autism by exposing rat fetuses to valproic acid (VPA) on the 12." | 3.85 | Postnatal treatment using curcumin supplements to amend the damage in VPA-induced rodent models of autism. ( Al-Askar, M; Al-Ayadhi, L; Bhat, RS; El-Ansary, A; Selim, M, 2017) |
| "There have been several reports of congenital malformations in the offspring of mothers who took valproic acid (VPA) during pregnancy as a treatment for epilepsy." | 3.85 | Fetal Valproate Syndrome. ( Bulut, C; Çaksen, H; Mutlu-Albayrak, H, 2017) |
| "Carbamazepine is one of the three most frequently prescribed antiepileptic drugs in pregnancy." | 3.83 | Concentrations of carbamazepine and carbamazepine-10,11-epoxide in maternal and umbilical cord blood at birth: Influence of co-administration of valproic acid or enzyme-inducing antiepileptic drugs. ( Brozmanova, H; Grundmann, M; Kacirova, I, 2016) |
| "Based on data from the EURAP observational International registry of antiepileptic drugs (AEDs) and pregnancy, we assessed changes in seizure control and subsequent AED changes in women who underwent attempts to withdraw valproic acid (VPA) during the first trimester of pregnancy." | 3.83 | Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2016) |
| "To compare the cognitive and language development of children born to women with epilepsy (WWE) exposed in utero to levetiracetam (LEV) or sodium valproate (VPA) and control children born to women without epilepsy not taking medication during pregnancy." | 3.80 | In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. ( Baker, GA; Bromley, RL; Cheyne, CP; García-Fiñana, M; Irwin, B; Morrow, J; Shallcross, R, 2014) |
| "To analyze seizure control, dose adjustments, and other changes of antiepileptic drug (AED) treatment during pregnancy in a large cohort of women with epilepsy entering pregnancy on monotherapy with carbamazepine, lamotrigine, phenobarbital, or valproate." | 3.79 | Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Tomson, T; Vajda, F, 2013) |
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 3.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| "Based on epidemiological data it is advised to whenever possible avoid valproic acid during pregnancy." | 3.78 | Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes. ( Boersma, C; de Jong-van den Berg, LT; Jentink, J; Postma, MJ, 2012) |
| "Children born to women with epilepsy (WWE), exposed in utero to levetiracetam (LEV, n = 51), were assessed for early cognitive development and compared to children exposed to sodium valproate in utero (VPA, n = 44) and a group of children representative of the general population (n = 97)." | 3.77 | Child development following in utero exposure: levetiracetam vs sodium valproate. ( Baker, GA; Bonnett, LJ; Bromley, RL; Irwin, B; Morrow, J; Shallcross, R, 2011) |
| "Health care providers reported lamotrigine exposure during pregnancy, and subsequent outcomes, on a voluntary basis." | 3.77 | Final results from 18 years of the International Lamotrigine Pregnancy Registry. ( Cunnington, MC; Ferber, S; Messenheimer, JA; Tennis, P; Weil, JG; Yerby, M, 2011) |
| " To assess the impact of influencing AED prescribing practices on spina bifida and cleft palate we searched the literature for estimates of the association between valproic acid or carbamazepine use during pregnancy and these defects and summarized the associations using meta-analyses." | 3.77 | Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States. ( Boulet, SL; Broussard, CS; Devine, OJ; Duwe, KN; Flak, AL; Gilboa, SM; Honein, MA; Moore, CA; Werler, MM, 2011) |
| "Valproic acid, which current guidelines suggest should be avoided in pregnancy, was most notable in terms of strength and breadth of its associations." | 3.77 | Use of antiepileptic medications in pregnancy in relation to risks of birth defects. ( Ahrens, KA; Anderka, MT; Bosco, JL; Gilboa, SM; Holmes, LB; Mitchell, AA; Werler, MM, 2011) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 3.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| " In utero, exposure to valproic acid (VPA) and phenytoin (PH) may cause congenital malformations and also withdrawal symptoms such as irritability, jitteriness and symptoms of hypoglycemia." | 3.76 | Neonatal episodic hypoglycemia: a finding of valproic acid withdrawal. ( Akçakuş, M; Akın, MA; Çoban, D; Güneş, T; Kurtoğlu, S, 2010) |
| "Between 1999 and 2004, we enrolled pregnant women with epilepsy who were taking a single antiepileptic agent (carbamazepine, lamotrigine, phenytoin, or valproate) in a prospective, observational, multicenter study in the United States and the United Kingdom." | 3.75 | Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. ( Baker, GA; Browning, N; Clayton-Smith, J; Cohen, M; Combs-Cantrell, DT; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2009) |
| "(1) Numerous follow-up studies of pregnancies in women with epilepsy show that valproic acid is more teratogenic than other antiepileptics." | 3.75 | Valproic acid: long-term effects on children exposed in utero. ( , 2009) |
| "Folic acid supplementation reduces the occurrence of neural tube defects (NTDs); however, it is not clear whether it protects against teratogenic effects of antiepileptic drugs." | 3.74 | Plasma vitamin values and antiepileptic therapy: case reports of pregnancy outcomes affected by a neural tube defect. ( Boisson, C; Candito, M; Gaucherand, P; Guéant, JL; Luton, D; Naimi, M; Rudigoz, JC; Van Obberghen, E, 2007) |
| " By contrast, offspring of rats exposed to carbamazepine (which at the dose used produced low plasma concentrations) or to generalized convulsive seizures showed no clear-cut evidence of dysplasias." | 3.74 | Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. ( Ben-Ari, Y; Depaulis, A; Jorquera, I; Manent, JB; Mazzucchelli, I; Perucca, E; Represa, A, 2007) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 3.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| "To investigate the effect of antiepileptic drugs, especially carbamazepine and valproate, on intelligence in prenatally exposed children of mothers with epilepsy." | 3.72 | Normal intelligence in children with prenatal exposure to carbamazepine. ( Bardy, A; Gaily, E; Granström, ML; Hiilesmaa, V; Isoaho, M; Kaaja, E; Kantola-Sorsa, E; Kotila, M; Matila, R; Nylund, T, 2004) |
| "The use of valproic acid during pregnancy has been associated with adverse fetal outcomes, including major and minor congenital malformations, intrauterine growth retardation (IUGR), hyperbilirubinemia, hepatotoxicity, transient hyperglycemia, and fetal and neonatal distress." | 3.71 | Septo-optic dysplasia as a manifestation of valproic acid embryopathy. ( Braddock, SR; McMahon, CL, 2001) |
| "A pregnant woman with epilepsy receiving VPA and ethosuximide (ESM) was given high-dose multivitamins from 13 to 28 weeks' gestation." | 3.70 | Valproate-induced biochemical abnormalities in pregnancy corrected by vitamins: a case report. ( Baggot, PJ; Kalamarides, JA; Shoemaker, JD, 1999) |
| "Neural tube defects (NTDs) are the most common of the major anomalies associated with in utero exposure to valproic acid." | 3.70 | Safe use of valproic acid during pregnancy. ( Kennedy, D; Koren, G, 1999) |
| "Twenty epileptic women were treated with valproate only during pregnancy and two were treated with valproate and carbamazepine." | 3.70 | Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate. ( Ebbesen, F; Holsteen, V; Hoseth, E; Joergensen, A; Kaad, PH; Moeller, M; Rix, M, 2000) |
| "We report a newborn with isolated aplasia cutis congenita of the scalp whose mother was treated with valproic acid during pregnancy." | 3.69 | Aplasia cutis congenita of the scalp in an infant exposed to valproic acid in utero. ( Berthier, M; Bonneau, D; Couet, D; Hubert, A; Larrègue, M; Oriot, D, 1994) |
| " Spina bifida aperta has been linked specifically to valproic acid (VPA) (estimated risk, 1 to 2%)." | 3.68 | The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. ( Brandenburg, H; Gaillard, HL; Grobbee, DE; Jahoda, MG; Los, FJ; Omtzigt, JG; Pijpers, L; Sachs, ES; Stewart, PA; Wladimiroff, JW, 1992) |
| "The effects of antiepileptic drugs (AED) on infants during pregnancy and delivery were studied in a total of 82 epileptic mothers on various monotherapies; 29 cases receiving valproic acid (VPA), 20 receiving phenytoin (PHT), 18 on carbamazepine (CBZ) and 15 on phenobarbital (PB)." | 3.68 | [Effects of antiepileptic drugs on delivery and early childhood--comparison among mono-therapies of valproic acid, phenytoin, carbamazepine and phenobarbital]. ( Ishikawa, S; Izumi, M; Okada, H; Takeda, A; Tanaka, H, 1991) |
| "An infant with dysmorphic features was born to an epileptic mother who had taken phenytoin and sodium valproate throughout pregnancy." | 3.68 | Neocerebellar hypoplasia in a neonate following intra-uterine exposure to anticonvulsants. ( Hope, PL; Lindenbaum, RH; Squier, W, 1990) |
| "A female neonate, whose mother had been treated throughout pregnancy with valproic acid and phenytoin, showed evident signs of liver damage, confirmed by laboratory investigations and biopsy." | 3.67 | Congenital liver damage after treatment of mother with valproic acid and phenytoin? ( Felding, I; Rane, A, 1984) |
| "To investigate whether treatment with valproic acid in pregnancy decreases adrenocorticotropic hormone and cortisol secretion, we measured their concentrations in maternal and umbilical cord blood from a patient receiving valproic acid." | 3.67 | Effect of treatment with sodium valproate on plasma adrenocorticotropic hormone and cortisol concentrations in pregnancy. ( Hatjis, CG; Pippitt, C; Rose, JC; Swain, M, 1985) |
| "Fetal exposure to valproic acid has recently been associated with an increased incidence of neural tube defects." | 3.67 | Prenatal detection of a neural tube defect after fetal exposure to valproic acid. ( Campbell, WA; Cassidy, SB; Ciarleglio, L; Nochimson, DJ; Vintzileos, AM; Weinbaum, PJ, 1986) |
| "The association of fetal and neonatal distress, birth measurements, major malformations, and minor anomalies was studied prospectively in 14 infants of women with epilepsy who were receiving valproic acid (VPA) monotherapy and in 12 infants of women with epilepsy who were receiving VPA in combination with other anticonvulsant drugs." | 3.67 | Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. ( Deichl, A; Hartmann, AM; Helge, H; Jäger-Roman, E; Jakob, S; Koch, S; Nau, H; Rating, D; Steldinger, R, 1986) |
| "Four infants who were exposed to sodium valproate or valproic acid during pregnancy are described." | 3.67 | Fetal valproate syndrome: is there a recognisable phenotype? ( Burn, J; Donnai, D; Tucker, SM; Winter, RM, 1987) |
| "Neural tube, craniofacial, and other congenital abnormalities have been described in infants born to mothers with epilepsy who were treated with valproic acid (VPA) during pregnancy." | 3.67 | Congenital abnormalities in two sibs exposed to valproic acid in utero. ( Anderson, L; Chitayat, D; Farrell, K; Hall, JG, 1988) |
| "The authors studied antipyrine disposition before and after delivery in 4 epileptic women whose anticonvulsant plasma level per dosage ratio was lowered during pregnancy, and compared the results to those found in nonpregnant women undergoing antiepileptic treatment (N = 6) and healthy women (N = 6)." | 3.66 | Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ( Chiba, K; Ishizaki, T; Nakazawa, Y; Tabuchi, T; Wagatsuma, T, 1982) |
| " In 2009, a review was published providing guidance for the dosing and therapeutic drug monitoring of antiepileptic drugs during pregnancy." | 2.66 | Therapeutic Drug Monitoring of Antiepileptic Drugs in Women with Epilepsy Before, During, and After Pregnancy. ( Arfman, IJ; Lambrechts, DA; Ter Horst, PGJ; Touw, DJ; Wammes-van der Heijden, EA; Wegner, I, 2020) |
| "These patients with refractory generalized epilepsy with sleep-related fast activities do not belong to a well-established syndromic category." | 2.66 | Genetic/idiopathic generalized epilepsies: Not so good as that! ( Crespel, A; Gelisse, P; Nilo, A, 2020) |
| "Epilepsy is one of the most common neurological complications in pregnancy; some women continue to use antiepileptic drugs (AEDs) to control seizures." | 2.66 | [Transfer Mechanisms of Compounds between Mother and Fetus/Infant Aimed for Optimized Medication during Pregnancy and Breastfeeding]. ( Furugen, A, 2020) |
| "Pregnancy was a strong determinant for discontinuation of psychotropic medication." | 2.53 | Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. ( Cowen, PJ; Evans, SJ; Freemantle, N; McCrea, RL; Nazareth, I; Osborn, DP; Petersen, I; Sammon, CJ, 2016) |
| "Pharmacotherapy for mood disorders during pregnancy is often complicated by pregnancy-related pharmacokinetic changes and the need for dose adjustments." | 2.50 | Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. ( Byatt, N; Deligiannidis, KM; Freeman, MP, 2014) |
| "For patients with migraine, the pregnancy labeling of VPA will be changed from Category "D" to "X." | 2.50 | Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions. ( Gentile, S, 2014) |
| "Full seizure control in the pre-pregnancy year, and adjusting antiepileptic drug doses to maintain plasma drug concentrations throughout pregnancy at values associated with seizure control before pregnancy, have major influences in preserving seizure control during pregnancy." | 2.50 | Treating epilepsy in pregnant women. ( Eadie, MJ, 2014) |
| "Epilepsy is one of the commonest chronic neurological disorders in developing countries." | 2.50 | [Epilepsy, antiepileptic drugs and disorders of reproductive functions of women]. ( Gregoraszczuk, EL; Grzyb, E; Kwiecińska, P, 2014) |
| "When treatment with valproic acid is the most appropriate treatment to achieve optimal seizure control, a number of measures can be implemented to minimise risk to the fetus." | 2.43 | Valproic acid in epilepsy : pregnancy-related issues. ( Genton, P; Semah, F; Trinka, E, 2006) |
| " If a dosage of AEDs in pregnant women with epilepsy is reduced to a reasonable minimum and the monotherapy is preferred, the risk of congenital malformations in their offspring can be minimized." | 2.42 | [Effect of anti-epileptic drugs on human placenta and the fetus]. ( Semczuk, M; Semczuk-Sikora, A, 2004) |
| "Neural tube defects were seen in 3% of the sample." | 2.41 | Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. ( Kozma, C, 2001) |
| "Valproic acid has probable teratogenic potential in humans but the number of reported cases is few and the spectrum of anomalies is broad so it is not possible to delineate a definite fetal valproate syndrome." | 2.37 | Congenital malformations associated with maternal use of valproic acid. ( Gauthier, M; Huot, C; Larbrisseau, A; Lebel, M, 1987) |
| " We investigated potential transgenerational adverse effects of valproate." | 1.72 | Transgenerational adverse effects of valproate? A patient report from 90 affected families. ( Bewley, S; Braillon, A; Hill, C; MacLennan, AH; Martin, M, 2022) |
| "Planned pregnancy was the only independent factor significantly associated with decreased risk of adverse pregnancy outcomes (OR, 0." | 1.72 | Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China. ( Jiang, W; Jiang, Y; Ma, L; Shi, X; Song, C; Wang, Y; Xia, L; Zhang, Y; Zhao, J, 2022) |
| "Logistic regression analysis showed that maternal age over 31 years, family histories of fetal malformation, and conception after assisted fertility treatment, and also dosage of valproate, carbamazepine, and topiramate, made statistically significant (P<0." | 1.62 | The contribution of non-drug factors to fetal malformation in anti-seizure-medication-treated pregnancy. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJE, 2021) |
| "Prepregnancy reduction in VPA dosage reduced the hazard of fetal malformations, whereas ceasing intake of the drug decreased the hazard to one similar to that which applies in the general population, but at a cost of decreased control of epileptic seizures during the pregnancies studied." | 1.56 | Pregnancy after valproate withdrawal-Fetal malformations and seizure control. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJE, 2020) |
| " A dose-response relationship was demonstrated and the risk of NDs was more particularly increased for an exposure to VPA during the second or third trimesters of pregnancy." | 1.56 | Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. ( Blotiere, PO; Coste, J; Dray-Spira, R; Mikaeloff, Y; Miranda, S; Peyre, H; Ramus, F; Weill, A; Zureik, M, 2020) |
| "To study the risk of intellectual disability and delayed development in childhood milestones among children of women who used valproate or other AEDs during pregnancy." | 1.56 | Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones. ( Christensen, J; Daugaard, CA; Dreier, JW; Pedersen, L; Sun, Y, 2020) |
| "Its use in pregnancy is associated with increased risks of congenital malformations and adverse neurodevelopment in the offspring and may be associated with an increased risk of attention-deficit/hyperactivity disorder (ADHD)." | 1.51 | Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Risk for Attention-Deficit/Hyperactivity Disorder in Offspring. ( Brikell, I; Christensen, J; Dalsgaard, S; Dreier, JW; Pedersen, L; Sun, Y, 2019) |
| " Interestingly, regarding VPA dosage, we found that women taking equal or more than 700 mg/day of VPA have lower scores on empowerment in all dimensions compared with women with a VPA dosage lower than 700 mg/day." | 1.51 | Level of empowerment and decision-making style of women with epilepsy in childbirth age. ( Canevini, MP; Cutica, I; Pravettoni, G; Riva, S; Turner, K; Zambrelli, E, 2019) |
| "Focal epilepsy was diagnosed in 244 (69." | 1.51 | Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study. ( Bosak, M; Słowik, A; Turaj, W, 2019) |
| "Evidence for the comparative teratogenic risk of antiepileptic drugs is insufficient, particularly in relation to the dosage used." | 1.48 | Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2018) |
| " Maternal levels and dosing information were used for estimating the maternal apparent oral clearance and the paired umbilical cord and maternal levels for estimation of umbilical cord/maternal level ratios." | 1.42 | Serum levels of valproic acid during delivery in mothers and in umbilical cord - correlation with birth length and weight. ( Brozmanova, H; Grundmann, M; Kacirova, I, 2015) |
| "The treatment profile for epilepsy, seizure control, and maternal and neonatal outcomes in both groups were compared using Chi-square test or Fisher's exact test and Mann-Whitney U test." | 1.40 | Impact of planning of pregnancy in women with epilepsy on seizure control during pregnancy and on maternal and neonatal outcomes. ( Abe, K; Hamada, H; Minakami, H; Obata-Yasuoka, M; Yamada, T; Yoshikawa, H, 2014) |
| "Valproate is used for the treatment of epilepsy and other neuropsychological disorders and may be the only treatment option for women of childbearing potential." | 1.39 | Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. ( Christensen, J; Grønborg, TK; Parner, ET; Pedersen, LH; Schendel, D; Sørensen, MJ; Vestergaard, M, 2013) |
| " The mean dosage of AED for valproate was 498 mg/day and carbamazepine was 555 mg/day." | 1.39 | Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. ( Begum, S; Sarma, SP; Thomas, SV, 2013) |
| "Epilepsy is one of the most common neurological diseases in the world." | 1.39 | [Valproic acid concentration in the blood serum of pregnant women and umbilical cord blood in relation to the condition of the newborn--case studies]. ( Breborowicz, GH; Chuchracki, M; Florek, E; Hassan-Bartz, M; Krzyścin, M; Kulza, M; Miller, R; Napierała, M; Wachowiak, A; Wozniak, A, 2013) |
| " Neurologists had progressively prescribed valproate less frequently and in lower dosage than other classes of practitioner over the 10-year study period, with a parallel decrease in occurrence of fetal malformations in pregnancies referred to the Register." | 1.38 | The prescribing of antiepileptic drugs for pregnant Australian women. ( Eadie, MJ; Graham, J; Hitchcock, AA; Hollingworth, S; Horgan, D; Lander, CM; O'Brien, TJ; Roten, A; Vajda, FJ, 2012) |
| " These changes tended to parallel prescribing trends in the wider community, except for valproate, whose prescribing in the overall community increased as its prescribing, and its dosage prescribed, decreased in pregnancy." | 1.36 | Changing patterns of antiepileptic drug use in pregnant Australian women. ( Eadie, MJ; Graham, J; Hitchcock, AA; Hollingworth, S; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| "Antiepileptic drugs (AED) as transplacental agents are known to have adverse effects on fetal development." | 1.36 | Transplacental genotoxicity of antiepileptic drugs: animal model and pilot study on mother/newborn cohort. ( Bakulic, TI; Demarin, V; Fucic, A; Gjergja, R; Jazbec, AM; Katic, J; Markovic, D; Miškov, S; Stojković, R; Zeljezic, D, 2010) |
| "Epilepsy has been associated with poor obstetric outcomes that could be the result of the epilepsy itself or a direct effect of anti-epileptic medication on placentation." | 1.35 | Phenytoin but not valproate directly affected in vitro trophoblast differentiation. ( Anin, S; Bates, MD; Chadwick, D; Neilson, JP; Quenby, SM; Vince, GS, 2008) |
| " Unlike the situation for the other drugs, the malformation rate in those exposed to valproate increased with increasing maternal drug dosage (P<0." | 1.33 | Maternal valproate dosage and foetal malformations. ( Eadie, MJ; Vajda, FJ, 2005) |
| "The incidence of birth defects in relation to specific AEDs was: valproate (16." | 1.32 | The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. ( Graham, J; Hitchcock, A; Lander, C; O'Brien, TJ; Vajda, FJ, 2003) |
| " However, there is no information available on the number of therapeutic abortions, or the different types of epilepsy or drug dosage in the two treatment groups." | 1.32 | Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. ( Källén, B; Wide, K; Winbladh, B, 2004) |
| "Autism has been described in association with a variety of medical and genetic conditions." | 1.31 | Fetal valproate syndrome and autism: additional evidence of an association. ( Cunningham, M; Hersh, JH; Kerr, B; King, J; Stephan, M; Williams, G, 2001) |
| "Ideally any pregnancy in a woman being treated for epilepsy should be planned, and both an obstetrician and a neurologist should be consulted." | 1.31 | Craniosynostosis and fetal exposure to sodium valproate. ( Barcik, U; Bourgeois, M; El Ghouzzi, V; Lajeunie, E; Renier, D; Thorne, JA, 2001) |
| "Metopic craniosynostosis may be an adverse effect of valproic acid exposed fetus." | 1.31 | [Metopic craniosynostosis, probable effect of intrauterine exposure to maternal valproate treatment]. ( Bensouda, B; Bruel, H; Chabrolle, JP; Degre, S; Ickowicz, V; Poinsot, J; Simon, A, 2001) |
| " Poor compliance may contribute to the occurrence of status epilepticus, resulting in the need for substantial increases in anticonvulsant dosing to suppress seizures." | 1.30 | Status epilepticus during pregnancy. A case report. ( Licht, EA; Sankar, R, 1999) |
| "One also had features of infantile autism." | 1.29 | Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. ( Chesler, N; Christianson, AL; Kromberg, JG, 1994) |
| "Juvenile myoclonic epilepsy is a relatively common, though under diagnosed, form of epilepsy that commences in adolescence." | 1.29 | Juvenile myoclonic epilepsy. ( Buchanan, N, 1995) |
| " The frequency of withdrawal symptoms was significantly related to the dose of valproate given to the mothers in the third trimester, and there was a tendency for both the frequency of the minor abnormalities and the major malformations to be related to the valproate dosage in the first trimester." | 1.29 | Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. ( Ebbesen, F; Thisted, E, 1993) |
| "Carbamazepine was the antiepileptic drug prescribed most frequently followed by valproic acid." | 1.28 | [The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy]. ( Bülau, P; Fröscher, W; Herrmann, R; Hildenbrand, G; Niesen, M; Penin, H, 1991) |
| "Only when the epilepsy is uncontrolled despite high plasma concentrations which cannot be raised because of side effects, a second drug should be given." | 1.27 | [Pharmacotherapy of epilepsy--current problems and controversies]. ( Schmidt, D, 1983) |
| "The effects of pregnancy on seizure excitability as well as antiepileptic drug disposition and efficacy were studied in the mouse during late gestation." | 1.27 | Effects of pregnancy on seizure threshold and the disposition and efficacy of antiepileptic drugs in the mouse. ( Kuhnz, W; Löscher, W; Nau, H, 1985) |
| " The mechanisms responsible for these effects have not been elucidated and possibly include decreased bioavailability or compliance, increased metabolic clearance, or decreased plasma protein binding." | 1.27 | Effects of pregnancy on antiepileptic drug utilization. ( Levy, RH; Yerby, MS, 1985) |
| "Spina Bifida, Congenital Heart Defects, Clefts, Diaphragmatic Hernia and Trisomy 18 were more frequent than expected among babies with maternal epilepsy." | 1.27 | Maternal epilepsy and birth defects: a case-control study in the Italian Multicentric Registry of Birth Defects (IPIMC). ( Bertollini, R; Mastroiacovo, P; Segni, G, 1985) |
| "The incidence of malformations in fetal mice exposed to phenytoin depends on drug dosage and the strain of mice." | 1.26 | Teratogenic effects of anticonvulsants. ( Paulson, GW; Paulson, RB, 1981) |
| " VPA was excreted in the neonates with a mean half-life of 47 +/- 15 hr (n = 8) which is approximately 4 times the mean value found in adult epileptics." | 1.26 | Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. ( Häuser, I; Helge, H; Koch, S; Nau, H; Rating, D, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 58 (18.18) | 18.7374 |
| 1990's | 45 (14.11) | 18.2507 |
| 2000's | 70 (21.94) | 29.6817 |
| 2010's | 107 (33.54) | 24.3611 |
| 2020's | 39 (12.23) | 2.80 |
| Authors | Studies |
|---|---|
| Christensen, J | 7 |
| Trabjerg, BB | 1 |
| Sun, Y | 5 |
| Gilhus, NE | 4 |
| Bjørk, MH | 2 |
| Tomson, T | 12 |
| Dreier, JW | 5 |
| Müffelmann, B | 1 |
| Hagemann, A | 1 |
| Knaak, N | 1 |
| Bien, CG | 1 |
| Rakitin, A | 1 |
| Kurvits, K | 1 |
| Laius, O | 1 |
| Uusküla, M | 1 |
| Haldre, S | 1 |
| Martin, M | 1 |
| Hill, C | 1 |
| Bewley, S | 2 |
| MacLennan, AH | 1 |
| Braillon, A | 2 |
| Gaudio, M | 1 |
| Konstantara, E | 1 |
| Joy, M | 1 |
| van Vlymen, J | 1 |
| de Lusignan, S | 1 |
| Błaszczyk, B | 1 |
| Miziak, B | 1 |
| Pluta, R | 1 |
| Czuczwar, SJ | 1 |
| Vajda, FJE | 7 |
| O'Brien, TJ | 15 |
| Graham, JE | 6 |
| Hitchcock, AE | 1 |
| Perucca, P | 4 |
| Lander, CM | 12 |
| Eadie, MJ | 16 |
| Zoega, H | 1 |
| Leinonen, MK | 1 |
| Cohen, JM | 1 |
| Furu, K | 1 |
| Gissler, M | 1 |
| Hálfdánarson, Ó | 1 |
| Igland, J | 1 |
| Alvestad, S | 1 |
| La Neve, A | 1 |
| Falcicchio, G | 1 |
| Trojano, M | 1 |
| Boero, G | 1 |
| Gruppuso, PA | 1 |
| Ahmed, R | 1 |
| Adashi, EY | 1 |
| Shi, X | 1 |
| Wang, Y | 1 |
| Zhang, Y | 1 |
| Song, C | 1 |
| Jiang, Y | 1 |
| Zhao, J | 1 |
| Xia, L | 1 |
| Ma, L | 1 |
| Jiang, W | 1 |
| Meador, KJ | 11 |
| Manière-Guerrero, I | 1 |
| Bonizzoni, E | 5 |
| Battino, D | 8 |
| Clinard, F | 1 |
| Mathieu-Huart, A | 1 |
| Perucca, E | 8 |
| Pouzaud, F | 1 |
| Thomas, SV | 7 |
| Vajda, F | 11 |
| Rousselle, C | 1 |
| O'Brien, T | 5 |
| Graham, J | 13 |
| Hitchcock, A | 7 |
| Lander, C | 6 |
| Eadie, M | 4 |
| Pekoz, MT | 1 |
| Aslan-Kara, K | 1 |
| Tekin, B | 1 |
| Gurses, C | 1 |
| Yeni, SN | 1 |
| Bozdemir, H | 1 |
| Keskin-Guler, S | 1 |
| Ataklı, D | 1 |
| Gul, G | 1 |
| Eren, F | 1 |
| Sarı, H | 1 |
| Gul, ZB | 1 |
| Ceyhan-Dirican, A | 1 |
| Genc, F | 1 |
| Bicer-Gomceli, Y | 1 |
| Ozkara, C | 2 |
| Delil, S | 1 |
| Atalar, AC | 1 |
| Bebek, N | 1 |
| Baykan, B | 1 |
| Bora, İ | 1 |
| Bican-Demir, A | 1 |
| Mısırlı, CH | 1 |
| Tutkavul, K | 1 |
| Velioglu, SK | 1 |
| Ilhan-Algin, D | 1 |
| Erdinc, O | 1 |
| Saygi, S | 1 |
| Tezer-Fılık, I | 1 |
| Apaydın-Dogan, E | 1 |
| Akyol, A | 1 |
| Kamisli, O | 1 |
| Yalcın, AD | 1 |
| Cakmak, G | 1 |
| Ersoy, A | 1 |
| Ustun-Ozek, S | 1 |
| Halac, G | 1 |
| Kutlu, G | 1 |
| Tantik-Pak, A | 1 |
| Yücel, SP | 1 |
| Fantaneanu, TA | 1 |
| Thornton, HF | 1 |
| Zhang, T | 1 |
| Bercovici, E | 1 |
| Hrazdil, C | 1 |
| Ikeda, KM | 1 |
| Kassiri, J | 1 |
| Suller Marti, A | 1 |
| Pana, R | 1 |
| Rezazadeh, A | 1 |
| Kobayashi, E | 1 |
| Bui, E | 1 |
| Charlton, R | 1 |
| Damase-Michel, C | 1 |
| Hurault-Delarue, C | 1 |
| Gini, R | 1 |
| Loane, M | 2 |
| Pierini, A | 1 |
| Puccini, A | 1 |
| Neville, A | 2 |
| Snowball, J | 1 |
| Morris, JK | 3 |
| Jackson, A | 2 |
| Ward, H | 1 |
| Bromley, RL | 5 |
| Deshpande, C | 1 |
| Vasudevan, P | 1 |
| Scurr, I | 1 |
| Dean, J | 2 |
| Shannon, N | 1 |
| Berg, J | 1 |
| Holder, S | 1 |
| Baralle, D | 1 |
| Clayton-Smith, J | 10 |
| Aykan, DA | 1 |
| Ergün, Y | 1 |
| Keni, RR | 1 |
| Jose, M | 2 |
| A S, R | 1 |
| Baishya, J | 1 |
| Sankara Sarma, P | 1 |
| Harris, L | 1 |
| Lowes, O | 1 |
| Angus-Leppan, H | 4 |
| Arfman, IJ | 1 |
| Wammes-van der Heijden, EA | 1 |
| Ter Horst, PGJ | 1 |
| Lambrechts, DA | 1 |
| Wegner, I | 1 |
| Touw, DJ | 1 |
| Moghim, MM | 1 |
| Cock, H | 1 |
| Kinton, L | 1 |
| Synnott Wells, M | 1 |
| Shankar, R | 2 |
| Suri, R | 1 |
| Socol, DK | 1 |
| Gitlin, M | 1 |
| Lebedevs, T | 1 |
| Gan, M | 1 |
| Teoh, SWK | 1 |
| Brown, P | 1 |
| Toledo, M | 1 |
| Mostacci, B | 1 |
| Bosak, M | 2 |
| Jedrzejzak, J | 1 |
| Thomas, RH | 2 |
| Salas-Puig, J | 1 |
| Biraben, A | 1 |
| Schmitz, B | 2 |
| Hitchcock, AA | 8 |
| Davies, P | 2 |
| Reuber, M | 1 |
| Grunewald, R | 1 |
| Howell, S | 1 |
| Dickson, J | 1 |
| Dennis, G | 1 |
| Shanmugarajah, P | 1 |
| Tsironis, T | 1 |
| Brockington, A | 1 |
| Nilo, A | 1 |
| Gelisse, P | 1 |
| Crespel, A | 1 |
| Furugen, A | 1 |
| Robson, J | 1 |
| Moss, N | 1 |
| McGettigan, P | 1 |
| Beardsley, SJ | 1 |
| Lovegrove, E | 1 |
| Dezateux, C | 1 |
| Coste, J | 1 |
| Blotiere, PO | 1 |
| Miranda, S | 1 |
| Mikaeloff, Y | 1 |
| Peyre, H | 1 |
| Ramus, F | 1 |
| Zureik, M | 1 |
| Weill, A | 1 |
| Dray-Spira, R | 1 |
| Daugaard, CA | 2 |
| Pedersen, L | 2 |
| Kaplan, YC | 1 |
| Demir, O | 1 |
| Seshachala, BB | 1 |
| Lathikakumari, AM | 1 |
| Murali, S | 1 |
| Kumar, AS | 1 |
| Hughes, JE | 1 |
| Buckley, N | 1 |
| Looney, Y | 1 |
| Kirwan, G | 1 |
| Curran, S | 1 |
| Doherty, CP | 1 |
| Mullooly, M | 1 |
| Bennett, KE | 1 |
| Ajinkya, S | 1 |
| Fox, J | 1 |
| Lekoubou, A | 1 |
| Pariente, G | 1 |
| Leibson, T | 1 |
| Shulman, T | 1 |
| Adams-Webber, T | 1 |
| Barzilay, E | 1 |
| Nulman, I | 1 |
| Al-Askar, M | 1 |
| Bhat, RS | 1 |
| Selim, M | 1 |
| Al-Ayadhi, L | 1 |
| El-Ansary, A | 1 |
| Casassus, B | 2 |
| Veroniki, AA | 1 |
| Rios, P | 1 |
| Cogo, E | 1 |
| Straus, SE | 1 |
| Finkelstein, Y | 1 |
| Kealey, R | 1 |
| Reynen, E | 1 |
| Soobiah, C | 1 |
| Thavorn, K | 1 |
| Hutton, B | 1 |
| Hemmelgarn, BR | 1 |
| Yazdi, F | 1 |
| D'Souza, J | 1 |
| MacDonald, H | 1 |
| Tricco, AC | 1 |
| Wise, J | 1 |
| Womersley, K | 1 |
| Wiedemann, K | 1 |
| Stüber, T | 1 |
| Rehn, M | 1 |
| Frieauff, E | 1 |
| Patel, N | 1 |
| Viguera, AC | 1 |
| Baldessarini, RJ | 1 |
| Friedrich, L | 1 |
| Sruk, A | 1 |
| Bielen, I | 1 |
| Pennell, PB | 6 |
| Jazayeri, D | 1 |
| Li, K | 1 |
| Li, J | 1 |
| Gu, J | 1 |
| Guo, X | 1 |
| Gao, T | 1 |
| Li, D | 1 |
| Liu, RSN | 1 |
| Wieck, A | 1 |
| Jones, S | 1 |
| Craig, J | 7 |
| Lindhout, D | 11 |
| Sabers, A | 6 |
| Garne, E | 2 |
| Addor, MC | 1 |
| Barisic, I | 2 |
| Bianchi, F | 1 |
| Gatt, M | 1 |
| Lanzoni, M | 1 |
| Lynch, C | 1 |
| Mokoroa, O | 1 |
| Nelen, V | 1 |
| O'Mahony, MT | 1 |
| Randrianaivo-Ranjatoelina, H | 1 |
| Rissmann, A | 1 |
| Tucker, D | 1 |
| de Walle, HEK | 1 |
| Zymak-Zakutnia, N | 1 |
| Rankin, J | 1 |
| Macfarlane, A | 1 |
| Greenhalgh, T | 1 |
| Galappatthy, P | 1 |
| Liyanage, CK | 1 |
| Lucas, MN | 1 |
| Jayasekara, DTLM | 1 |
| Abhayaratna, SA | 1 |
| Weeraratne, C | 1 |
| De Abrew, K | 1 |
| Gunaratne, PS | 1 |
| Gamage, R | 1 |
| Wijeyaratne, CN | 1 |
| Barton, S | 1 |
| Nadebaum, C | 1 |
| Anderson, VA | 1 |
| Reutens, DC | 1 |
| Wood, AG | 1 |
| Sen, A | 1 |
| Nashef, L | 1 |
| Heneghan, C | 1 |
| Aronson, JK | 1 |
| Putignano, D | 1 |
| Clavenna, A | 1 |
| Campi, R | 1 |
| Canevini, MP | 3 |
| Vignoli, A | 2 |
| Beghi, E | 1 |
| Bortolotti, A | 1 |
| Fortino, I | 1 |
| Merlino, L | 1 |
| Bonati, M | 1 |
| Brikell, I | 1 |
| Dalsgaard, S | 1 |
| Cohen, MJ | 2 |
| May, R | 1 |
| Loblein, H | 1 |
| Conrad, T | 1 |
| Baker, GA | 7 |
| Kalayjian, LA | 4 |
| Kanner, A | 2 |
| Liporace, JD | 3 |
| Privitera, M | 2 |
| Loring, DW | 6 |
| Perera, C | 1 |
| Patterson, S | 1 |
| Bruxner, G | 1 |
| Turner, K | 1 |
| Cutica, I | 1 |
| Riva, S | 1 |
| Zambrelli, E | 1 |
| Pravettoni, G | 1 |
| Richards, N | 1 |
| Reith, D | 1 |
| Stitely, M | 1 |
| Smith, A | 1 |
| Watkins, LV | 1 |
| Cock, HR | 1 |
| Morgan, S | 1 |
| Raine, J | 1 |
| Hudson, I | 1 |
| Kacirova, I | 3 |
| Grundmann, M | 3 |
| Brozmanova, H | 3 |
| Gürer, R | 1 |
| Aydın, Ş | 1 |
| Słowik, A | 1 |
| Turaj, W | 1 |
| Bromley, R | 3 |
| Journel, H | 1 |
| Odent, S | 1 |
| Wood, A | 2 |
| Williams, J | 1 |
| Cuthbert, V | 1 |
| Hackett, L | 1 |
| Aslam, N | 1 |
| Malm, H | 2 |
| James, G | 1 |
| Westbom, L | 1 |
| Day, R | 1 |
| Ladusans, E | 1 |
| Bruce, I | 1 |
| Walker, R | 1 |
| Sidhu, S | 1 |
| Dyer, C | 1 |
| Ashworth, J | 1 |
| Hindley, D | 1 |
| Diaz, GA | 1 |
| Rawson, M | 1 |
| Turnpenny, P | 1 |
| Vajda, FJ | 10 |
| Grønborg, TK | 1 |
| Sørensen, MJ | 1 |
| Schendel, D | 1 |
| Parner, ET | 1 |
| Pedersen, LH | 1 |
| Vestergaard, M | 2 |
| Kmietowicz, Z | 1 |
| Singh, S | 1 |
| Begum, S | 1 |
| Sarma, SP | 1 |
| Abe, K | 1 |
| Hamada, H | 1 |
| Yamada, T | 1 |
| Obata-Yasuoka, M | 1 |
| Minakami, H | 1 |
| Yoshikawa, H | 1 |
| Shallcross, R | 3 |
| Cheyne, CP | 2 |
| García-Fiñana, M | 2 |
| Irwin, B | 4 |
| Morrow, J | 6 |
| Veiby, G | 2 |
| Daltveit, AK | 2 |
| Engelsen, BA | 2 |
| Kulza, M | 1 |
| Miller, R | 1 |
| Wozniak, A | 1 |
| Napierała, M | 1 |
| Wachowiak, A | 1 |
| Hassan-Bartz, M | 1 |
| Krzyścin, M | 1 |
| Chuchracki, M | 1 |
| Breborowicz, GH | 1 |
| Florek, E | 1 |
| Deligiannidis, KM | 1 |
| Byatt, N | 1 |
| Freeman, MP | 1 |
| Gentile, S | 1 |
| Smith, V | 1 |
| Brown, N | 1 |
| Weston, J | 1 |
| Adab, N | 3 |
| Greenhalgh, J | 1 |
| Sanniti, A | 1 |
| McKay, AJ | 1 |
| Tudur Smith, C | 1 |
| Marson, AG | 1 |
| Briggs, M | 1 |
| Gummery, A | 1 |
| Kneen, R | 1 |
| Mawer, G | 5 |
| Klein, P | 1 |
| Sargar, KM | 1 |
| Herman, TE | 1 |
| Siegel, MJ | 1 |
| Grzyb, E | 1 |
| Kwiecińska, P | 1 |
| Gregoraszczuk, EL | 1 |
| Vlasov, PN | 1 |
| Homberg, V | 1 |
| Janszky, J | 1 |
| Khan, SJ | 1 |
| Fersh, ME | 1 |
| Ernst, C | 1 |
| Klipstein, K | 1 |
| Albertini, ES | 1 |
| Lusskin, SI | 1 |
| Solignac, I | 1 |
| Petersen, I | 1 |
| McCrea, RL | 1 |
| Sammon, CJ | 1 |
| Osborn, DP | 1 |
| Evans, SJ | 1 |
| Cowen, PJ | 1 |
| Freemantle, N | 1 |
| Nazareth, I | 1 |
| Vanya, M | 1 |
| Devosa, I | 1 |
| Szok, D | 1 |
| Bártfai, G | 1 |
| Balon, R | 1 |
| Riba, M | 2 |
| Gotlib, D | 1 |
| Perelstein, E | 1 |
| Kurlander, J | 1 |
| Zivin, K | 1 |
| Muzik, M | 1 |
| Mutlu-Albayrak, H | 1 |
| Bulut, C | 1 |
| Çaksen, H | 1 |
| Kikuchi, N | 1 |
| Ohira, S | 1 |
| Asaka, R | 1 |
| Tanaka, K | 1 |
| Takatsu, A | 1 |
| Shiozawa, T | 1 |
| Masson, M | 1 |
| Huberfeld, G | 1 |
| Richa, S | 1 |
| Henry, C | 1 |
| Gaillard, R | 1 |
| Kasradze, S | 1 |
| Gogatishvili, N | 1 |
| Lomidze, G | 1 |
| Ediberidze, T | 1 |
| Lazariashvili, M | 1 |
| Khomeriki, K | 1 |
| Mamukadze, S | 1 |
| Metreveli, M | 1 |
| Gagoshidze, T | 1 |
| Tatishvili, N | 1 |
| Wen, X | 1 |
| Hartzema, A | 1 |
| Delaney, JA | 1 |
| Brumback, B | 1 |
| Liu, X | 1 |
| Egerman, R | 1 |
| Roth, J | 1 |
| Segal, R | 1 |
| Würtz, AM | 1 |
| Rytter, D | 1 |
| Vestergaard, CH | 1 |
| Bech, BH | 1 |
| Whitehall, J | 1 |
| Smith, J | 1 |
| Harden, CL | 3 |
| Sethi, NK | 1 |
| Larsen, K | 1 |
| Blichfeldt, S | 1 |
| Sahlholdt, L | 1 |
| Rasmussen, JO | 1 |
| Seidahmed, MZ | 2 |
| Miqdad, AM | 1 |
| Al-Dohami, HS | 1 |
| Shareefi, OM | 1 |
| Browning, N | 1 |
| Combs-Cantrell, DT | 1 |
| Cohen, M | 1 |
| Hauser, WA | 2 |
| Gronseth, GS | 2 |
| French, JA | 2 |
| Wiebe, S | 2 |
| Thurman, D | 2 |
| Koppel, BS | 2 |
| Kaplan, PW | 2 |
| Robinson, JN | 2 |
| Hopp, J | 2 |
| Ting, TY | 2 |
| Gidal, B | 2 |
| Hovinga, CA | 2 |
| Wilner, AN | 2 |
| Vazquez, B | 2 |
| Holmes, L | 2 |
| Krumholz, A | 2 |
| Finnell, R | 2 |
| Hirtz, D | 2 |
| Le Guen, C | 2 |
| Al-Mendalawi, MD | 1 |
| Liu, YH | 1 |
| Wang, L | 1 |
| Huang, YG | 1 |
| Trivedi, A | 1 |
| Halliday, R | 1 |
| Waters, K | 1 |
| Levison, J | 1 |
| Hollingworth, S | 2 |
| Singh, RP | 1 |
| Dhariwal, D | 1 |
| Bhujel, N | 1 |
| Shaikh, Z | 1 |
| Nishikawa, H | 1 |
| Solanki, G | 1 |
| Dover, MS | 1 |
| Jentink, J | 2 |
| Loane, MA | 1 |
| Dolk, H | 1 |
| de Jong-van den Berg, LT | 2 |
| Fucic, A | 1 |
| Stojković, R | 1 |
| Miškov, S | 1 |
| Zeljezic, D | 1 |
| Markovic, D | 1 |
| Gjergja, R | 1 |
| Katic, J | 1 |
| Jazbec, AM | 1 |
| Bakulic, TI | 1 |
| Demarin, V | 1 |
| Bonnett, LJ | 1 |
| Berle, JØ | 1 |
| Solberg, DK | 1 |
| Spigset, O | 1 |
| Çoban, D | 1 |
| Kurtoğlu, S | 1 |
| Akın, MA | 1 |
| Akçakuş, M | 1 |
| Güneş, T | 1 |
| Cummings, C | 1 |
| Stewart, M | 1 |
| Stevenson, M | 1 |
| Nelson, J | 1 |
| Cunnington, MC | 1 |
| Weil, JG | 1 |
| Messenheimer, JA | 1 |
| Ferber, S | 1 |
| Yerby, M | 1 |
| Tennis, P | 1 |
| Gilboa, SM | 2 |
| Broussard, CS | 1 |
| Devine, OJ | 1 |
| Duwe, KN | 1 |
| Flak, AL | 1 |
| Boulet, SL | 1 |
| Moore, CA | 1 |
| Werler, MM | 2 |
| Honein, MA | 1 |
| Horgan, D | 1 |
| Roten, A | 2 |
| Ahrens, KA | 1 |
| Bosco, JL | 1 |
| Mitchell, AA | 1 |
| Anderka, MT | 1 |
| Holmes, LB | 2 |
| Mawhinney, E | 2 |
| Campbell, J | 1 |
| Russell, A | 2 |
| Smithson, W | 1 |
| Parsons, L | 2 |
| Robertson, I | 1 |
| Morrison, P | 2 |
| Liggan, B | 2 |
| Delanty, N | 2 |
| Hunt, S | 1 |
| Boersma, C | 1 |
| Postma, MJ | 1 |
| Kozhokaru, AB | 1 |
| Karlov, VA | 1 |
| Zhidkova, IA | 1 |
| Serkina, AV | 1 |
| Smithson, WH | 1 |
| Morrison, PJ | 1 |
| Hunt, SJ | 1 |
| Crawford, P | 1 |
| Kajantie, E | 1 |
| Kivirikko, S | 1 |
| Kääriäinen, H | 1 |
| Peippo, M | 1 |
| Somer, M | 1 |
| Coyle, H | 2 |
| Kini, U | 3 |
| Ozkinay, F | 1 |
| Cogulu, O | 1 |
| Gunduz, C | 1 |
| Yilmaz, D | 1 |
| Kultursay, N | 1 |
| Gosakan, R | 1 |
| von Knorring, N | 1 |
| Stewart, P | 1 |
| Servillo, G | 1 |
| Striano, P | 1 |
| Striano, S | 1 |
| Tortora, F | 1 |
| Boccella, P | 1 |
| De Robertis, E | 1 |
| Rossano, F | 1 |
| Briganti, F | 1 |
| Tufano, R | 1 |
| Yerby, MS | 5 |
| Houge, G | 1 |
| Fiskerstrand, T | 1 |
| Øyen, N | 1 |
| Semczuk-Sikora, A | 2 |
| Rogowska, W | 1 |
| Semczuk, M | 2 |
| Gagliardi, JP | 1 |
| Krishnan, KR | 1 |
| Taubøll, E | 1 |
| Gjerstad, L | 1 |
| Henriksen, T | 1 |
| Husby, H | 1 |
| Gaily, E | 2 |
| Kantola-Sorsa, E | 1 |
| Hiilesmaa, V | 1 |
| Isoaho, M | 1 |
| Matila, R | 1 |
| Kotila, M | 1 |
| Nylund, T | 1 |
| Bardy, A | 1 |
| Kaaja, E | 1 |
| Granström, ML | 2 |
| Wu, SP | 1 |
| Shyu, MK | 1 |
| Liou, HH | 1 |
| Gau, CS | 1 |
| Lin, CJ | 1 |
| Wide, K | 1 |
| Winbladh, B | 1 |
| Källén, B | 2 |
| Shorvon, SD | 1 |
| Vinten, J | 2 |
| Ayres, J | 1 |
| Baker, G | 1 |
| Fryer, A | 2 |
| Gorry, J | 1 |
| Gregg, J | 1 |
| Nicolaides, P | 1 |
| Pickering, L | 1 |
| Tunnicliffe, L | 1 |
| Chadwick, DW | 1 |
| Solinas, C | 1 |
| Cook, M | 2 |
| ten Berg, K | 1 |
| van Oppen, AC | 1 |
| Nikkels, PG | 1 |
| Gittenberger-de Groot, AC | 1 |
| van der Voet, GB | 1 |
| Brilstra, EH | 1 |
| Curtis, V | 1 |
| Penovich, P | 1 |
| Alsdorf, R | 1 |
| Wyszynski, DF | 1 |
| O'Brien, MD | 1 |
| Gilmour-White, SK | 1 |
| Genton, P | 2 |
| Semah, F | 1 |
| Trinka, E | 1 |
| Artama, M | 1 |
| Isojärvi, JI | 1 |
| Auvinen, A | 1 |
| Ben-Menachem, E | 1 |
| Finnell, RH | 1 |
| Smith, JC | 1 |
| Wolff, MC | 1 |
| Luef, G | 1 |
| Pittschieler, S | 1 |
| Ohman, I | 1 |
| Viinikainen, K | 1 |
| Eriksson, K | 1 |
| Mönkkönen, A | 1 |
| Aikiä, M | 1 |
| Nieminen, P | 1 |
| Heinonen, S | 1 |
| Kälviäinen, R | 1 |
| Candito, M | 1 |
| Naimi, M | 1 |
| Boisson, C | 1 |
| Rudigoz, JC | 1 |
| Gaucherand, P | 1 |
| Guéant, JL | 1 |
| Luton, D | 1 |
| Van Obberghen, E | 1 |
| Chakravarty, A | 1 |
| Mukherjee, A | 1 |
| Roy, D | 1 |
| Manent, JB | 1 |
| Jorquera, I | 1 |
| Mazzucchelli, I | 1 |
| Depaulis, A | 1 |
| Ben-Ari, Y | 1 |
| Represa, A | 1 |
| Quenby, SM | 1 |
| Anin, S | 1 |
| Bates, MD | 1 |
| Chadwick, D | 3 |
| Vince, GS | 1 |
| Neilson, JP | 1 |
| Reynolds, MF | 1 |
| Sisk, EC | 1 |
| Rasgon, NL | 1 |
| Rodríguez-Vázquez, M | 1 |
| Carrascosa-Romero, MC | 1 |
| Pardal-Fernández, JM | 1 |
| Iniesta, I | 1 |
| Hiilesmaa, VK | 1 |
| Bardy, AH | 1 |
| Teramo, KA | 1 |
| Castilla, E | 1 |
| Meinardi, H | 3 |
| Robert, E | 5 |
| Löfkvist, E | 1 |
| Mauguiere, F | 1 |
| Koch, S | 5 |
| Göpfert-Geyer, I | 1 |
| Jäger-Roman, E | 4 |
| Jakob, S | 2 |
| Huth, H | 1 |
| Hartmann, A | 1 |
| Rating, D | 5 |
| Helge, H | 5 |
| Curran, AC | 1 |
| ten Kate, LP | 1 |
| Swagemakers, ML | 1 |
| Weemhoff, RA | 1 |
| van Eck, JH | 1 |
| Kaneko, S | 3 |
| Otani, K | 3 |
| Fukushima, Y | 4 |
| Sato, T | 2 |
| Nomura, Y | 2 |
| Ogawa, Y | 2 |
| Philbert, A | 3 |
| Pedersen, B | 2 |
| Friis, ML | 1 |
| Fukuda, T | 1 |
| Kuroki, Y | 1 |
| Robert, JM | 2 |
| Lapras, C | 1 |
| Schmidt, D | 2 |
| Froescher, W | 1 |
| Gugler, R | 1 |
| Niesen, M | 2 |
| Hoffmann, F | 1 |
| Bantz, EW | 1 |
| Felding, I | 1 |
| Rane, A | 1 |
| DiLiberti, JH | 1 |
| Farndon, PA | 1 |
| Dennis, NR | 1 |
| Curry, CJ | 1 |
| Niermeijer, MF | 1 |
| Dalens, B | 1 |
| Raynaud, EJ | 1 |
| Gaulme, J | 1 |
| Paulson, GW | 1 |
| Paulson, RB | 1 |
| Nau, H | 7 |
| Häuser, I | 1 |
| Cairney, P | 1 |
| Hornabrook, RW | 1 |
| Ainsworth, JW | 1 |
| Dam, M | 2 |
| Chiba, K | 1 |
| Ishizaki, T | 1 |
| Tabuchi, T | 1 |
| Wagatsuma, T | 1 |
| Nakazawa, Y | 1 |
| Christianson, AL | 1 |
| Chesler, N | 1 |
| Kromberg, JG | 1 |
| Buchanan, N | 1 |
| Bavoux, F | 1 |
| Fournier-Perhilou, AI | 1 |
| Wood, C | 1 |
| Francoual, C | 1 |
| Boccara, JF | 1 |
| Hubert, A | 1 |
| Bonneau, D | 1 |
| Couet, D | 1 |
| Berthier, M | 1 |
| Oriot, D | 1 |
| Larrègue, M | 1 |
| Ylagan, LR | 1 |
| Budorick, NE | 1 |
| Martin, PJ | 1 |
| Millac, PA | 1 |
| Thisted, E | 1 |
| Ebbesen, F | 2 |
| Kondo, T | 2 |
| Kan, R | 1 |
| Takeda, A | 2 |
| Nakane, Y | 1 |
| Sharony, R | 1 |
| Garber, A | 1 |
| Viskochil, D | 1 |
| Schreck, R | 1 |
| Platt, LD | 1 |
| Ward, R | 1 |
| Buehler, BA | 1 |
| Graham, JM | 1 |
| Thurston, JH | 1 |
| Hauhart, RE | 1 |
| Gunatilake, SB | 1 |
| Donnai, D | 2 |
| Finnerty, M | 1 |
| Levin, Z | 1 |
| Miller, LJ | 1 |
| Lösche, G | 1 |
| Espinasse, M | 1 |
| Manouvrier, S | 1 |
| Boute, O | 1 |
| Farriaux, JP | 1 |
| Hockey, A | 1 |
| Bower, C | 1 |
| Goldblatt, J | 1 |
| Knowles, S | 1 |
| Bradaï, R | 1 |
| Kennedy, D | 2 |
| Koren, G | 2 |
| Dardennes, R | 1 |
| Even, C | 1 |
| Baggot, PJ | 1 |
| Kalamarides, JA | 1 |
| Shoemaker, JD | 1 |
| Licht, EA | 1 |
| Sankar, R | 1 |
| Patterson, V | 1 |
| Canger, R | 1 |
| Fumarola, C | 1 |
| Guidolin, L | 1 |
| Mamoli, D | 1 |
| Palmieri, C | 1 |
| Molteni, F | 1 |
| Granata, T | 1 |
| Hassibi, P | 1 |
| Zamperini, P | 1 |
| Pardi, G | 1 |
| Avanzini, G | 1 |
| Chaudron, LH | 1 |
| Jefferson, JW | 1 |
| Joergensen, A | 1 |
| Hoseth, E | 1 |
| Kaad, PH | 1 |
| Moeller, M | 1 |
| Holsteen, V | 1 |
| Rix, M | 1 |
| Fairgrieve, SD | 1 |
| Jackson, M | 1 |
| Jonas, P | 1 |
| Walshaw, D | 1 |
| White, K | 1 |
| Montgomery, TL | 1 |
| Burn, J | 2 |
| Lynch, SA | 1 |
| Kozma, C | 1 |
| Williams, G | 1 |
| King, J | 1 |
| Cunningham, M | 1 |
| Stephan, M | 1 |
| Kerr, B | 1 |
| Hersh, JH | 1 |
| Harvey, EA | 1 |
| Coull, BA | 1 |
| Huntington, KB | 1 |
| Khoshbin, S | 1 |
| Hayes, AM | 1 |
| Ryan, LM | 1 |
| Bruel, H | 2 |
| Chabrolle, JP | 2 |
| Amusini, P | 1 |
| Levesque, L | 1 |
| Iskandar, K | 1 |
| Poinsot, J | 2 |
| Duncan, S | 1 |
| Mercho, S | 1 |
| Lopes-Cendes, I | 1 |
| Seni, MH | 1 |
| Benjamin, A | 1 |
| Dubeau, F | 1 |
| Andermann, F | 1 |
| Andermann, E | 1 |
| McMahon, CL | 1 |
| Braddock, SR | 1 |
| Iqbal, MM | 1 |
| Sohhan, T | 1 |
| Mahmud, SZ | 1 |
| Lajeunie, E | 1 |
| Barcik, U | 1 |
| Thorne, JA | 1 |
| El Ghouzzi, V | 1 |
| Bourgeois, M | 1 |
| Renier, D | 1 |
| Sodhi, P | 1 |
| Poddar, B | 1 |
| Parmar, V | 1 |
| Bescoby-Chambers, N | 1 |
| Forster, P | 1 |
| Bates, G | 1 |
| Bensouda, B | 1 |
| Simon, A | 1 |
| Ickowicz, V | 1 |
| Degre, S | 1 |
| Laskowska, M | 1 |
| Leszczyńska-Gorzelak, B | 1 |
| Oleszczuk, J | 1 |
| Similä, S | 1 |
| von Wendt, L | 1 |
| Hartikainen-Sorri, AL | 2 |
| Kääpä, P | 1 |
| Saukkonen, AL | 1 |
| Alexander, FW | 1 |
| Omtzigt, JG | 3 |
| Los, FJ | 2 |
| Pijpers, L | 2 |
| Buntinx, IM | 1 |
| Cornel, MC | 1 |
| Grobbee, DE | 1 |
| Jahoda, MG | 1 |
| Brandenburg, H | 1 |
| Stewart, PA | 1 |
| Gaillard, HL | 1 |
| Sachs, ES | 1 |
| Wladimiroff, JW | 1 |
| Leavitt, A | 1 |
| Erickson, DM | 1 |
| McCormick, KB | 1 |
| Loewenson, RB | 1 |
| Sells, CJ | 1 |
| Benedetti, TJ | 1 |
| Dravet, C | 1 |
| Julian, C | 1 |
| Legras, C | 1 |
| Magaudda, A | 1 |
| Guerrini, R | 1 |
| Soulayrol, S | 1 |
| Giraud, N | 1 |
| Mesdjian, E | 1 |
| Trentin, G | 1 |
| Meijer, JW | 1 |
| Fröscher, W | 1 |
| Herrmann, R | 1 |
| Bülau, P | 1 |
| Penin, H | 1 |
| Hildenbrand, G | 1 |
| Hauck, RS | 1 |
| Ehlers, K | 1 |
| Sharma, M | 1 |
| Agrawal, P | 1 |
| Orrell, RW | 1 |
| Tanaka, H | 1 |
| Izumi, M | 1 |
| Okada, H | 1 |
| Ishikawa, S | 1 |
| Palea, KM | 1 |
| Anai, T | 1 |
| Hirota, Y | 1 |
| Oga, M | 1 |
| Yoshimatsu, J | 1 |
| Miyakawa, I | 1 |
| Cohen, LS | 1 |
| Heller, VL | 1 |
| Squier, W | 1 |
| Hope, PL | 1 |
| Lindenbaum, RH | 1 |
| Markovitz, PJ | 1 |
| Calabrese, JR | 1 |
| Robinek, F | 1 |
| Czeizel, E | 1 |
| Haddad, J | 1 |
| Messer, J | 1 |
| Willard, D | 1 |
| Chevallier, B | 1 |
| Nègre, V | 1 |
| Bidat, E | 1 |
| Lagardère, B | 1 |
| Oakeshott, P | 1 |
| Piccione, E | 1 |
| Ticconi, C | 1 |
| Cennamo, M | 1 |
| Legius, E | 1 |
| Jaeken, J | 1 |
| Eggermont, E | 1 |
| Guibaud, S | 1 |
| Guibaud, P | 1 |
| Gossrau, R | 1 |
| Merker, HJ | 1 |
| Günther, T | 1 |
| Graf, R | 1 |
| Vormann, J | 1 |
| Hatjis, CG | 1 |
| Rose, JC | 1 |
| Pippitt, C | 1 |
| Swain, M | 1 |
| Weinbaum, PJ | 1 |
| Cassidy, SB | 1 |
| Vintzileos, AM | 1 |
| Campbell, WA | 1 |
| Ciarleglio, L | 1 |
| Nochimson, DJ | 1 |
| Heikkinen, J | 1 |
| Nikiforow, R | 1 |
| Deichl, A | 1 |
| Hartmann, AM | 1 |
| Steldinger, R | 1 |
| Brown, EG | 1 |
| Bertollini, R | 2 |
| Mastroiacovo, P | 2 |
| Lammer, EJ | 1 |
| Sever, LE | 1 |
| Oakley, GP | 1 |
| Huot, C | 1 |
| Gauthier, M | 1 |
| Lebel, M | 1 |
| Larbrisseau, A | 1 |
| Curran, MA | 1 |
| Winter, RM | 1 |
| Tucker, SM | 1 |
| Hirano, T | 1 |
| Tsuru, N | 1 |
| Maeda, T | 1 |
| Tsuruoka, M | 1 |
| Chitayat, D | 1 |
| Farrell, K | 1 |
| Anderson, L | 1 |
| Hall, JG | 1 |
| Kuhnz, W | 1 |
| Löscher, W | 1 |
| Garden, AS | 1 |
| Benzie, RJ | 1 |
| Hutton, EM | 1 |
| Gare, DJ | 1 |
| Levy, RH | 1 |
| Segni, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PSG in Valproate-induced Nocturnal Enuresis in Children[NCT04191863] | 260 participants (Actual) | Observational | 2018-09-01 | Completed | |||
| A Pilot Study of Prophylactic Management of Lamotrigine for Bipolar Disorder in Pregnant Women[NCT03774641] | 20 participants (Anticipated) | Observational | 2018-12-03 | Recruiting | |||
| Lamotrigine Pregnancy Registry (LAM05)[NCT01064297] | 3,416 participants (Actual) | Observational | 2001-11-30 | Completed | |||
| Effects and Consequences for Mother and Child From Treatment for Depression, A Prospective Randomized, Placebo- Controlled, Trial With Internet-based Cognitive Behavior Therapy and Sertraline or Placebo for Moderate Depression in Pregnancy[NCT02185547] | Phase 4 | 17 participants (Actual) | Interventional | 2016-02-21 | Terminated (stopped due to Difficulties in recruiting participants.) | ||
| Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions[NCT02292056] | 50 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | |||
| A Study of Divalproex Sodium in Children With Autism Spectrum Disorder and Epileptiform EEG[NCT01170325] | Phase 2 | 0 participants (Actual) | Interventional | 2010-06-30 | Withdrawn | ||
| Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study[NCT00021866] | 331 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| Prophylactic Use of Immediate Postpartum Sertraline to Prevent Postpartum Depression: A Double Blind Randomized Placebo Controlled Trial[NCT02235064] | 2 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Low recruitment, completion of funding cycle) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy with valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 14 |
| First Exposure During Second Trimester | 1 |
| First Exposure During Third Trimester | 0 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 1 |
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy without valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 12 |
| First Exposure During Second Trimester | 0 |
| First Exposure During Third Trimester | 1 |
| All Trimesters | 13 |
Among lamotrigine monotherapy exposures: live births, fetal deaths, induced abortions with birth defects, and live births without defects. Due to the likelihood of inconsistent identification of birth defects among spontaneous losses, fetal deaths, and induced abortions without reported birth defects, these offspring were not included in analyses. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 35 |
| First Exposure During Second Trimester | 4 |
| First Exposure During Third Trimester | 1 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 40 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine monotherapy. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of major congenital malformations are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 31 | 1 | 3 | 1523 | 10 | 33 | 98 |
| First Exposure During Second Trimester | 4 | 0 | 0 | 91 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 17 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy with valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 14 | 0 | 2 | 134 | 1 | 4 | 6 |
| First Exposure During Second Trimester | 1 | 0 | 0 | 6 | 1 | 0 | 0 |
| First Exposure During Third Trimester | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The number of live births, fetal deaths with pregnancy loss occurring >=20 weeks gestation, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy without valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. Although birth defects may not have been reported, they cannot be ruled out. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 11 | 0 | 1 | 418 | 3 | 19 | 22 |
| First Exposure During Second Trimester | 0 | 0 | 0 | 25 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy with valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hydrocephalus/spina bifida | Meningomyelocele | Microcephaly | Orofacial clefts | Cardiac septal defects | Transposition of great vessels | Ventricular hypoplasia | Pulmonary stenosis | Pyloric stenosis | Gastroschisis | Club foot | Polydactyly | |
| Doses Lower Than Prescribed | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Prescribed Doses | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy without valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neural tube defect | Cardiac septal defect/murmur | Coarctation of aorta | Tetralogy of Fallot | Esophageal defects | Hypospadias | Hydroencephalopathy | Omphalocele | Extra digit | Skin tags on ear | |
| Doses Higher Than Prescribed | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| Doses Lower Than Prescribed | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Prescribed Doses | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
The number of infants with the reported MCM following first trimester lamotrigine monotherapy exposure were counted. Registry personnel contacted the enrolling physician to obtain information on the pregnancy outcome, lamotrigine dosing and duration of exposure, and use of concomitant antiepileptic drugs during pregnancy. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anencephaly | Orofacial clefts | Hypoplastic left heart/left ventricle hypoplasia | Transposition of great vessels | Ventricular septal defects | Minor heart defect, unspecified | Pulmonary stenosis | Hydronephrosis | Renal defect (absent, polysystic, fluid on kidney) | Cortical dysplasis | Hypospadias | Pyloric stenosis | Diaphragmatic hernia | Congenital atresia of anus | Hip dislocation | Club feet | Polydactyly | Epidermolysis bullosa | Light spot across entire abdomen | |
| Dose Higher Than Prescribed | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Doses Lower Than Prescribed | 2 | 2 | 1 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| Prescribed Doses | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Unknown Maximal Dose in Exposed Trimester | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The Antidepressant Side-Effect Checklist (ASEC) was employed to detect any adverse reaction to treatment regimens (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 1 |
"Patients met with single psychiatrist (co-investigator), blinded to group assignment, who evaluated the patient using Edinburgh Postpartum Depression Screen, Hamilton Depression Rating Scale, Global Assessment of Functioning Scale, and clinical assessment~0 = No postpartum depression up to 12 weeks following discharge from hospital~1 = Postpartum depression up to 12 weeks following discharge from hospital" (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 4734 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 3033 |
| Placebo | 2750 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 3685 |
55 reviews available for valproic acid and Complications, Pregnancy
| Article | Year |
|---|---|
Epilepsy in Pregnancy-Management Principles and Focus on Valproate.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism | 2022 |
Effects of Maternal Use of Antiseizure Medications on Child Development.
Topics: Anticonvulsants; Child; Child Development; Epilepsy; Female; Folic Acid; Humans; Pregnancy; Pregnanc | 2022 |
Therapeutic Drug Monitoring of Antiepileptic Drugs in Women with Epilepsy Before, During, and After Pregnancy.
Topics: Anticonvulsants; Drug Monitoring; Epilepsy; Female; Humans; Postpartum Period; Pregnancy; Pregnancy | 2020 |
Expert opinion: use of valproate in girls and women of childbearing potential with epilepsy: recommendations and alternatives based on a review of the literature and clinical experience-a European perspective.
Topics: Anticonvulsants; Child; Epilepsy; Epilepsy, Generalized; Female; Humans; Pregnancy; Pregnancy Compli | 2021 |
Genetic/idiopathic generalized epilepsies: Not so good as that!
Topics: Abnormalities, Drug-Induced; Adult; Comorbidity; Contraindications, Drug; Death, Sudden; Epilepsy, G | 2020 |
[Transfer Mechanisms of Compounds between Mother and Fetus/Infant Aimed for Optimized Medication during Pregnancy and Breastfeeding].
Topics: Anticonvulsants; Benzodiazepines; Biological Transport; Breast Feeding; Cell Line; Epilepsy; Female; | 2020 |
Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications.
Topics: Anticonvulsants; Breast Feeding; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam | 2021 |
Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant, Newbo | 2017 |
Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis.
Topics: Anticonvulsants; Autistic Disorder; Bayes Theorem; Breast Feeding; Carbamazepine; Child; Epilepsy; F | 2017 |
Valproate: life-saving, life-changing.
Topics: Anticonvulsants; England; Epilepsy; Female; Humans; Maternal Exposure; Practice Guidelines as Topic; | 2018 |
Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Decision Making; E | 2018 |
'Conceivably Neglected' - Are prescribers sufficiently aware of the risks of prescribing sodium valproate to women with mental illness?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Epilepsy; Female; | 2019 |
Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.
Topics: Antidepressive Agents; Carbamazepine; Drug Monitoring; Female; Humans; Lamotrigine; Mood Disorders; | 2014 |
Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Bipolar Di | 2014 |
Treating epilepsy in pregnant women.
Topics: Anticonvulsants; Congenital Abnormalities; Epilepsy; Female; Humans; Intellectual Disability; Matern | 2014 |
Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child.
Topics: Age Factors; Anticonvulsants; Carbamazepine; Child; Developmental Disabilities; Epilepsy; Female; Hu | 2014 |
Prevention of migraine attacks. First-choice treatments.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tric | 2015 |
[Epilepsy, antiepileptic drugs and disorders of reproductive functions of women].
Topics: Anticonvulsants; Epilepsy; Female; Fetal Diseases; Humans; Infertility, Female; Polycystic Ovary Syn | 2014 |
[Algorithms of using valproic acid drugs in women].
Topics: Algorithms; Anticonvulsants; Contraindications; Epilepsy; Female; Humans; Pregnancy; Pregnancy Compl | 2015 |
Is carbamazepine a human teratogen?
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Carbamazepine; Epilepsy; Female; Fet | 2016 |
Bipolar Disorder in Pregnancy and Postpartum: Principles of Management.
Topics: Antipsychotic Agents; Bipolar Disorder; Electroconvulsive Therapy; Female; Humans; Lactation; Lamotr | 2016 |
Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records.
Topics: Adult; Antipsychotic Agents; Drug Utilization; Electronic Health Records; Female; Humans; Infant, Ne | 2016 |
[Preconceptional and perinatal challenges of pregnancy in women with epilepsy].
Topics: Adult; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epileps | 2016 |
Guideline adherence for mentally ill reproductive-aged women on treatment with valproic acid: a retrospective chart review.
Topics: Abnormalities, Drug-Induced; Contraception Behavior; Female; Folic Acid; Guideline Adherence; Humans | 2016 |
Epileptic disorders in pregnancy: an overview.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Folic Acid; Hemorrhag | 2008 |
Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Birth Weight; Cognition Disorders; Contraindications; | 2009 |
Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurolo
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Birth Weight; Cognition Disorders; Contraindications; | 2009 |
The teratogenic risk of antiepileptic drug polytherapy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Therapy, Combination; Female; Fetal Di | 2010 |
Valproic acid monotherapy in pregnancy and major congenital malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Case-Control Studies; Cohort Studies; Female; Humans; | 2010 |
[Treatment of bipolar disorder during pregnancy and in the postpartum period].
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Contraindications; Female; Humans; Lactati | 2011 |
Epilepsy and pregnancy.
Topics: Anticonvulsants; Embryonic and Fetal Development; Epilepsy; Female; Fetal Diseases; Folic Acid; Huma | 2002 |
Management issues for women with epilepsy: neural tube defects and folic acid supplementation.
Topics: Adult; Animals; Anticonvulsants; Carbamazepine; Cleft Lip; Cleft Palate; Epilepsy; Female; Folic Aci | 2003 |
[Effect of anti-epileptic drugs on human placenta and the fetus].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Embryonic and Fetal Development; Epilepsy; Female; Fet | 2004 |
Women are not the same as men: specific clinical issues for female patients with bipolar disorder.
Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Counseling; Dibenzothiaze | 2005 |
Teratogenicity of sodium valproate.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Animals; Autistic Disorder; Cleft Lip; | 2005 |
Management of epilepsy in women.
Topics: Anticonvulsants; Child; Contraceptives, Oral, Combined; Contraindications; Developmental Disabilitie | 2005 |
Valproic acid in epilepsy : pregnancy-related issues.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Autistic Disorder; Epilepsy; Female; Humans; Infant, N | 2006 |
Role of valproate across the ages. Treatment of epilepsy in adults.
Topics: Adult; Age Factors; Anticonvulsants; Child; Developmental Disabilities; Epilepsy; Female; Fertility; | 2006 |
Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Contraceptives, Oral; Epilepsy; Female; Hormone | 2007 |
Antiepileptic drugs as human teratogens.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Phenobarbital | 2008 |
ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Breast Feed | 2008 |
The epileptic mother and her child.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Breast Feeding; Carbamazepine; Epilepsy; Female; Fetal | 1982 |
Pregnancy, teratogenesis, and epilepsy.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Epilepsy; Female; Fetus; Humans; Infant, Newb | 1994 |
Valproic acid use in psychiatry: issues in treating women of reproductive age.
Topics: Adult; Animals; Antimanic Agents; Female; Humans; Pregnancy; Pregnancy Complications; Teratogens; Va | 1998 |
[Current trends in the therapeutic use of thymic regulators].
Topics: Anticonvulsants; Antidepressive Agents; Depressive Disorder; Female; Humans; Lithium; Mood Disorders | 1998 |
Mood stabilizers during breastfeeding: a review.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Breast Feeding; Carbamazepine; Cyclohexanecarbo | 2000 |
Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anticonvulsants; Epilepsy; Face; Female | 2001 |
The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation.
Topics: Adult; Anticonvulsants; Antimanic Agents; Carbamazepine; Female; Humans; Lactation; Lithium; Pregnan | 2001 |
Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms.
Topics: Abnormalities, Drug-Induced; Animals; Disease Models, Animal; Female; Humans; Maternal-Fetal Exchang | 1991 |
Valproic acid.
Topics: Dosage Forms; Drug Administration Schedule; Drug Interactions; Female; Humans; Infant, Newborn; Milk | 1991 |
[Fetal disease caused by sodium valproate. Apropos of a case].
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complic | 1989 |
[Problems of neurological drug therapy in pregnancy].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antiparkinson Agents; Carbamazepine; Chelating Agents; | 1989 |
Teratogen update: valproic acid.
Topics: Abnormalities, Drug-Induced; Animals; Epidemiologic Methods; Epilepsy; Female; Humans; Infant, Newbo | 1987 |
Congenital malformations associated with maternal use of valproic acid.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Bone and Bones; Epilepsy; Facial Bones; Female | 1987 |
Three cases of delivery under sodium valproate--placental transfer, milk transfer and probable teratogenicity of sodium valproate.
Topics: Abnormalities, Drug-Induced; Adult; Epilepsy; Female; Fingers; Humans; Infant, Newborn; Male; Matern | 1988 |
6 trials available for valproic acid and Complications, Pregnancy
| Article | Year |
|---|---|
Cross-sectional evaluation of prescription of valproate and other antiepileptic drugs to pregnant women.
Topics: Anticonvulsants; Cross-Sectional Studies; Drug Prescriptions; Epilepsy; Female; Humans; Infant, Newb | 2021 |
In utero antiepileptic drug exposure: fetal death and malformations.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Cognition; Female; Fetal Death; | 2006 |
Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives.
Topics: Anticonvulsants; Contraceptives, Oral; Drug Combinations; Epilepsy; Female; Humans; Kinetics; Lamotr | 2006 |
[Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Akathisia, Drug-Induced; Anencephaly; Ant | 1983 |
Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome.
Topics: Anticonvulsants; Child; Drug Monitoring; Epilepsy; Female; Follow-Up Studies; Humans; Nervous System | 1996 |
[Evaluation of antiepileptic therapy during pregnancy].
Topics: Adult; Anticonvulsants; Apgar Score; Drug Therapy, Combination; Epilepsy; Female; Humans; Phenobarbi | 2002 |
258 other studies available for valproic acid and Complications, Pregnancy
| Article | Year |
|---|---|
Prenatal exposure to valproate and risk of congenital malformations-Could we have known earlier?-A population-based cohort study.
Topics: Anticonvulsants; Child; Cohort Studies; Denmark; Female; Humans; Male; Pregnancy; Pregnancy Complica | 2021 |
[Women with epilepsy before and during pregnancy: a case series of outpatient counseling in a tertiary epilepsy center].
Topics: Anticonvulsants; Counseling; Epilepsy; Female; Folic Acid; Humans; Lamotrigine; Levetiracetam; Outpa | 2022 |
Pre-pregnancy counseling for women with epilepsy: Can we do better?
Topics: Anticonvulsants; Counseling; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complications; Teratogen | 2021 |
Transgenerational adverse effects of valproate? A patient report from 90 affected families.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Cleft Lip; Cleft Palate; Drug-Related Side Ef | 2022 |
Valproate prescription to women of childbearing age in English primary care: repeated cross-sectional analyses and retrospective cohort study.
Topics: Adolescent; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cohort Studies; Contraceptio | 2022 |
Achieving neurologically desirable outcomes to pregnancy in women with epilepsy.
Topics: Anticonvulsants; Australia; Epilepsy; Female; Humans; Levetiracetam; Pregnancy; Pregnancy Complicati | 2022 |
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability.
Topics: Anticonvulsants; Autism Spectrum Disorder; Autistic Disorder; Carbamazepine; Child; Cohort Studies; | 2022 |
Seizure medication and planned pregnancy: balancing the risks and outcomes.
Topics: Anticonvulsants; Epilepsy; Family Planning Services; Female; Humans; Pregnancy; Pregnancy Complicati | 2022 |
Valproate Teratogenicity: A Moving Target.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complic | 2022 |
Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Male; Phenobarbital; Pregnanc | 2022 |
Proposal for reference values for the developmental effects of valproate based on human data using a benchmark dose approach.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benchmarking; Female; Humans; Pregnancy; Pregnancy Com | 2023 |
Specific fetal malformations following intrauterine exposure to antiseizure medication.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Carbamazepine; Female; Humans; Male; Pregna | 2023 |
Birth outcomes in pregnant women with epilepsy: A Nationwide multicenter study from Türkiye.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant; Infant, Newborn; Lamotrigine; Preg | 2023 |
Changes over 24 years in a pregnancy register - Teratogenicity and epileptic seizure control.
Topics: Anticonvulsants; Australia; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complication | 2023 |
Real-world practices for the care of women with epilepsy during pregnancy: A Canadian perspective.
Topics: Adult; Anticonvulsants; Canada; Epilepsy; Epilepsy, Generalized; Female; Humans; Pregnancy; Pregnanc | 2023 |
Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Child; Cohort Studies; Databases, Factual; Epi | 2019 |
Exome sequencing in patients with antiepileptic drug exposure and complex phenotypes.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child; Child, Preschool; Developmental Disabilities; E | 2020 |
Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy.
Topics: Adult; Anticonvulsants; Carbamazepine; Female; Folic Acid; Humans; India; Lamotrigine; Levetiracetam | 2020 |
Treatment decisions in women of childbearing age on valproate.
Topics: Adult; Anticonvulsants; Decision Making; Epilepsy; Female; Humans; Informed Consent; Patient Educati | 2020 |
Valproate risk form-Surveying 215 clinicians involving 4775 encounters.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Physicians | 2020 |
Standard of Care: Reasonable But Not Perfect.
Topics: Abnormalities, Drug-Induced; Adult; Arnold-Chiari Malformation; Female; Humans; Hydrocephalus; Infan | 2020 |
Analysis of Perinatal Women Attending a Mother and Baby Unit Taking Sodium Valproate or Lithium with a Diagnosis of Bipolar Affective Disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Breast Feeding; Female; Follow-Up Studies; Humans; Lithiu | 2020 |
Pregnancy after valproate withdrawal-Fetal malformations and seizure control.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Epilepsy; Female; Humans; Pregnancy; | 2020 |
The impact and challenges of the 2018 MHRA statement on the use of sodium valproate in women of childbearing age during the first year of implementation, in a UK epilepsy centre.
Topics: Adolescent; Adult; Anticonvulsants; Contraception; Contraindications, Drug; Cross-Sectional Studies; | 2020 |
First do no harm: valproate and medicines safety in pregnancy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complications; Valproic Acid | 2020 |
Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France.
Topics: Adult; Anticonvulsants; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Epilepsy | 2020 |
Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clonazepam; Denmark; Developmen | 2020 |
Folic acid dose, valproate, and fetal malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Female; Folic Acid; Humans; Pregnancy; Preg | 2021 |
Valproate usage in pregnancy: An audit from the Kerala Registry of Epilepsy and Pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Humans; India; Pregnancy; Pre | 2021 |
The contribution of non-drug factors to fetal malformation in anti-seizure-medication-treated pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Epilepsy; Female; Humans; Pregnancy; | 2021 |
Awareness, knowledge and practice of healthcare professionals following implementation of a Pregnancy Prevention Program for sodium valproate in Ireland: a multi-stakeholder cross-sectional study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cross-Sectional Studies; Female; General Practitioners | 2021 |
Contemporary trends in antiepileptic drug treatment among women of childbearing age with epilepsy in the United States: 2004-2015.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Pregnancy | 2021 |
Postnatal treatment using curcumin supplements to amend the damage in VPA-induced rodent models of autism.
Topics: Animals; Anticonvulsants; Autistic Disorder; Brain; Curcumin; Dietary Supplements; Disease Models, A | 2017 |
France bans sodium valproate use in case of pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Bipolar Disorder; Female; France; Humans; Pregnancy; P | 2017 |
Women still not being told about pregnancy risks of valproate.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Developmental Disabilities; Epilepsy; Female; Humans; | 2017 |
Prescription of Sodium Valproate as a Mood Stabiliser in Pregnancy.
Topics: Bipolar Disorder; Female; Humans; Pregnancy; Pregnancy Complications; Psychotic Disorders; Valproic | 2017 |
Fetal Valproate Syndrome - Still a Problem Today!
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cesarean Section; Drug Therapy, Combination; Ep | 2017 |
Mood-Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Dietary Supplements; Female; Fol | 2018 |
Women with epilepsy in childbearing age: Pregnancy-related knowledge, information sources, and antiepileptic drugs.
Topics: Adolescent; Adult; Anticonvulsants; Counseling; Croatia; Epilepsy; Female; Health Knowledge, Attitud | 2018 |
Antiepileptic Drugs in Pregnancy-Quick Decisions With Long-term Consequences.
Topics: Anticonvulsants; Child; Epilepsy; Female; Humans; Language; Mathematics; Pregnancy; Pregnancy Compli | 2018 |
Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications.
Topics: Abnormalities, Drug-Induced; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; Outcome Ass | 2018 |
The protective effect of polyunsaturated fatty acid intake during pregnancy against embryotoxicity of sodium valproate in mice.
Topics: Animals; Anticonvulsants; Embryonic Development; Fatty Acids, Omega-3; Female; Fetal Diseases; Folic | 2018 |
Weighing the risks of valproate in women who could become pregnant.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Contraindications, Drug; Developmental Disabilities; E | 2018 |
Dangers of valproate in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complic | 2018 |
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug | 2018 |
Prevalence of valproate syndrome in Europe from 2005 to 2014: A registry based multi-centre study.
Topics: Adult; Anticonvulsants; Cognitive Dysfunction; Congenital Abnormalities; Epilepsy; Europe; Female; H | 2018 |
Prescribing in pregnancy shows the weaknesses in pharmacovigilance.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Pharmacovigilance; Pregnancy; Pregnancy Complications; Va | 2018 |
Obstetric outcomes and effects on babies born to women treated for epilepsy during pregnancy in a resource limited setting: a comparative cohort study.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anticonvulsants; Body Height; Body Weight; Carbamazepine; | 2018 |
Memory dysfunction in school-aged children exposed prenatally to antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Dose-Response Relationship, Drug; Epilepsy; Female; Hu | 2018 |
Valproate-associated foetal malformations-Rates of occurrence, risks in attempted avoidance.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Epilepsy; Female; Humans; Pregnancy; | 2019 |
New regulations to cut valproate-exposed pregnancies.
Topics: Anticonvulsants; Epilepsy; Female; Government Regulation; Humans; Pregnancy; Pregnancy Complications | 2018 |
Sodium valproate: who knew what and when? Cumulative meta-analysis gives extra insights.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Meta-Analysis as Topic; Preg | 2019 |
Perinatal outcome and healthcare resource utilization in the first year of life after antiepileptic exposure during pregnancy.
Topics: Adult; Anticonvulsants; Databases, Factual; Epilepsy; Female; Health Resources; Humans; Infant; Infa | 2019 |
Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Risk for Attention-Deficit/Hyperactivity Disorder in Offspring.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; Denmark; Epil | 2019 |
Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age: The NEAD prospective observational study.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsy; Female; Humans; Lamotrigine; Learning; Memor | 2019 |
Level of empowerment and decision-making style of women with epilepsy in childbirth age.
Topics: Adolescent; Adult; Anticonvulsants; Decision Making; Empowerment; Epilepsy; Female; Humans; Middle A | 2019 |
Developmental outcomes at age four following maternal antiepileptic drug use.
Topics: Adult; Anticonvulsants; Carbamazepine; Child Development; Child, Preschool; Cohort Studies; Epilepsy | 2019 |
Valproate and the Pregnancy Prevention Programme: exceptional circumstances.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Drug and Narcotic Control; Europe; Female; Humans; Pre | 2019 |
Valproate and the Pregnancy Prevention Programme.
Topics: Epilepsy; Female; Humans; Pregnancy; Pregnancy Complications; Valproic Acid | 2019 |
Valproic acid concentrations in nursing mothers, mature milk, and breastfed infants in monotherapy and combination therapy.
Topics: Adult; Animals; Anticonvulsants; Breast Feeding; Drug Therapy, Combination; Epilepsy; Female; Humans | 2019 |
Outcomes of low-dose valproic acid treatment in patients with juvenile myoclonic epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Cross-Sectional Studies; Dose-Response Relationship, Drug; Femal | 2019 |
Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Cohort Studies; Epilepsy; Female; H | 2019 |
Use of antiepileptic drugs in women of fertile age.
Topics: Adolescent; Adult; Anticonvulsants; Denmark; Epilepsy; Female; Gabapentin; Humans; Lamotrigine; Leve | 2019 |
Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability.
Topics: Anticonvulsants; Consensus; Female; Humans; Intellectual Disability; Pregnancy; Pregnancy Complicati | 2019 |
Associations between particular types of fetal malformation and antiepileptic drug exposure in utero.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Epilepsy; Female; Fetal Diseases; Fructose; | 2013 |
Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.
Topics: Adolescent; Adult; Anticonvulsants; Autistic Disorder; Child; Child Development Disorders, Pervasive | 2013 |
Risks of in utero exposure to valproate.
Topics: Anticonvulsants; Autistic Disorder; Child Development Disorders, Pervasive; Epilepsy; Female; Humans | 2013 |
Valproate in pregnancy linked to autism in children.
Topics: Anticonvulsants; Autistic Disorder; Denmark; Epilepsy; Female; Humans; Incidence; Infant, Newborn; P | 2013 |
More drug studies need to include pregnant women, says bulletin.
Topics: Anticonvulsants; Clinical Trials as Topic; Drug Industry; Female; Humans; Hypnotics and Sedatives; M | 2013 |
Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry.
Topics: Anticonvulsants; Carbamazepine; Female; Humans; Lamotrigine; Phenobarbital; Pregnancy; Pregnancy Com | 2013 |
Prenatal valproate exposure is associated with autism spectrum disorder and childhood autism.
Topics: Anticonvulsants; Autistic Disorder; Child Development Disorders, Pervasive; Epilepsy; Female; Humans | 2013 |
Prenatal exposure to sodium valproate is associated with increased risk of childhood autism and autistic spectrum disorder.
Topics: Anticonvulsants; Autistic Disorder; Child Development Disorders, Pervasive; Epilepsy; Female; Humans | 2014 |
Valproate use during pregnancy was linked to autism spectrum disorder and childhood autism in offspring.
Topics: Anticonvulsants; Autistic Disorder; Child Development Disorders, Pervasive; Epilepsy; Female; Humans | 2013 |
[Valproic acid during pregnancy lowers IQ in children].
Topics: Anticonvulsants; Epilepsy; Female; Humans; Intellectual Disability; Maternal-Fetal Exchange; Nervous | 2013 |
Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; India; Pregna | 2013 |
Impact of planning of pregnancy in women with epilepsy on seizure control during pregnancy and on maternal and neonatal outcomes.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy | 2014 |
In utero exposure to levetiracetam vs valproate: development and language at 3 years of age.
Topics: Adult; Anticonvulsants; Child Development; Child, Preschool; Epilepsy; Female; Humans; Language Deve | 2014 |
Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Birth Weight; Cohort Studies; Epilepsy; Female; | 2014 |
[Valproic acid concentration in the blood serum of pregnant women and umbilical cord blood in relation to the condition of the newborn--case studies].
Topics: Adult; Anticonvulsants; Epilepsy; Female; Fetal Blood; Humans; Infant, Newborn; Pregnancy; Pregnancy | 2013 |
In brief: warning against use of valproate for migraine prevention during pregnancy.
Topics: Anticonvulsants; Child; Child Development; Child, Preschool; Female; Humans; Intelligence; Intellige | 2013 |
Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.
Topics: Anticonvulsants; Autistic Disorder; Child Development Disorders, Pervasive; Epilepsy; Female; Humans | 2014 |
IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child Development; Epilepsy; Female; Humans; Intellige | 2015 |
Fine-tuning risk assessment with antiepileptic drug use in pregnancy.
Topics: Anticonvulsants; Carbamazepine; Child Development; Epilepsy; Female; Humans; Intelligence; Lamotrigi | 2015 |
Valproate fetopathy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Diagnostic Imaging; Epilepsy; Female; Fetal Di | 2015 |
Valproate and pregnancy: think again.
Topics: Anticonvulsants; Carbamazepine; Child Development; Epilepsy; Female; Humans; Intelligence; Lamotrigi | 2015 |
Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; D | 2015 |
[Valproic acid responsible for low IQ].
Topics: Anticonvulsants; Carbamazepine; Child Development; Epilepsy; Female; Humans; Intelligence; Male; Pre | 2015 |
[Position Statement of Hungarian Epilepsy League: The use of valproate preparations for epilepsy in pregnancy and in women of childbearing age].
Topics: Adolescent; Adult; Anticonvulsants; Cognition; Contraception; Dose-Response Relationship, Drug; Drug | 2015 |
Fine-tuning risk assessment with antiepileptic drug use in pregnancy.
Topics: Anticonvulsants; Carbamazepine; Child Development; Epilepsy; Female; Humans; Intelligence; Male; Pre | 2015 |
Serum levels of valproic acid during delivery in mothers and in umbilical cord - correlation with birth length and weight.
Topics: Anticonvulsants; Biomarkers; Body Height; Body Weight; Delivery, Obstetric; Dose-Response Relationsh | 2015 |
[A girl with foetal valproate syndrome and autism spectrum disorder].
Topics: Anticonvulsants; Autistic Disorder; Child; Child Development Disorders, Pervasive; Epilepsy; Female; | 2016 |
Concentrations of carbamazepine and carbamazepine-10,11-epoxide in maternal and umbilical cord blood at birth: Influence of co-administration of valproic acid or enzyme-inducing antiepileptic drugs.
Topics: Adolescent; Adult; Anticonvulsants; Blood Chemical Analysis; Carbamazepine; Dose-Response Relationsh | 2016 |
France steps up warning measures for valproate drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Drug and Narcotic Control; Drug Information Services; | 2016 |
Should women of childbearing potential be prescribed valproate? a call to action.
Topics: Abnormalities, Drug-Induced; Bipolar Disorder; Contraception Behavior; Epilepsy; Female; Humans; Inf | 2016 |
Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP.
Topics: Adolescent; Adult; Anticonvulsants; Bayes Theorem; Cohort Studies; Epilepsy; Female; Humans; Interna | 2016 |
Fetal Valproate Syndrome.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child, Preschool; Craniofacial Abnormalities; Cryptorc | 2017 |
Prenatal sonographic diagnosis of fetal valproate syndrome: a case report.
Topics: Abnormalities, Drug-Induced; Adult; Female; Humans; Infant, Newborn; Japan; Pregnancy; Pregnancy Com | 2016 |
[Caution and warning: About valproate and pregnancy].
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Epilepsy; Female; Humans; Pregnancy; Pre | 2016 |
Cognitive functions in children exposed to antiepileptic drugs in utero - Study in Georgia.
Topics: Adult; Anticonvulsants; Child; Child Development; Child, Preschool; Cognition; Cohort Studies; Epile | 2017 |
Combining adverse pregnancy and perinatal outcomes for women exposed to antiepileptic drugs during pregnancy, using a latent trait model.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Florida; Humans; Infant, Low | 2017 |
Prenatal exposure to antiepileptic drugs and use of primary healthcare during childhood: a population-based cohort study in Denmark.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Denmark; Epilepsy; Femal | 2017 |
Valproate and babies.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Bipolar Disorder; Cross-Sectional Studies; Dose-Respon | 2008 |
[Valproate treatment during pregnancy: description of four cases with foetal valproate syndrome].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child; Child, Preschool; Developmental Disabilities; E | 2009 |
A case of fetal valproate syndrome with new features expanding the phenotype.
Topics: Abnormalities, Multiple; Anticonvulsants; Epilepsy, Post-Traumatic; Female; Fetus; Humans; Infant; P | 2009 |
Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Child, Preschool; Cognition; Developmental Disabilities; Dose | 2009 |
Pregnancy, delivery, and outcome for the child in maternal epilepsy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Apgar Score; Birth Weight; Congenital Abnormali | 2009 |
A case of fetal valproate syndrome with new features expanding the phenotype.
Topics: Abnormalities, Multiple; Anticonvulsants; Epilepsy; Female; Fetus; Humans; Infant; Phenotype; Pregna | 2009 |
Cognitive function after fetal exposure to antiepileptic drugs.
Topics: Anticonvulsants; Child, Preschool; Confounding Factors, Epidemiologic; Developmental Disabilities; E | 2009 |
Unilateral lung agenesis: coincidence or association with maternal valproate therapy?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Lung; Male; | 2009 |
Changing patterns of antiepileptic drug use in pregnant Australian women.
Topics: Anticonvulsants; Australia; Congenital Abnormalities; Epilepsy; Female; Humans; Linear Models; Pract | 2010 |
Valproic acid: long-term effects on children exposed in utero.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Cohort Studies; Contraindications; Dose | 2009 |
Role of parental risk factors in the aetiology of isolated non-syndromic metopic craniosynostosis.
Topics: Anticonvulsants; Chi-Square Distribution; Craniosynostoses; Epilepsy; Female; Fertility Agents, Fema | 2010 |
Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Congenital Abnormalities; Dose-Response Rel | 2010 |
Transplacental genotoxicity of antiepileptic drugs: animal model and pilot study on mother/newborn cohort.
Topics: Adult; Animals; Animals, Newborn; Anticonvulsants; Cohort Studies; Epilepsy; Female; Humans; Infant, | 2010 |
Valproic acid use in pregnancy and congenital malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy | 2010 |
Child development following in utero exposure: levetiracetam vs sodium valproate.
Topics: Anticonvulsants; Child Development; Child, Preschool; Cognition; Epilepsy; Female; Humans; Infant; L | 2011 |
Neonatal episodic hypoglycemia: a finding of valproic acid withdrawal.
Topics: Anticonvulsants; Epilepsy; Female; Glucose; Humans; Hypoglycemia; Infant, Newborn; Infant, Newborn, | 2010 |
Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Case-Control Studies; Child, Preschool; Developmental Disabilities; | 2011 |
Final results from 18 years of the International Lamotrigine Pregnancy Registry.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Female; Humans; Infant; Lamotrigine; Pregnanc | 2011 |
Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States.
Topics: Anticonvulsants; Carbamazepine; Cleft Palate; Female; Humans; Pregnancy; Pregnancy Complications; Pr | 2011 |
The prescribing of antiepileptic drugs for pregnant Australian women.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Epilepsy; Female; Fetus; Humans; Log | 2012 |
Use of antiepileptic medications in pregnancy in relation to risks of birth defects.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Hu | 2011 |
Valproate and the risk for congenital malformations: Is formulation and dosage regime important?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complic | 2012 |
Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Carbamazepine; Cost-Benefit Analysis; Epil | 2012 |
Teratogenesis in repeated pregnancies in antiepileptic drug-treated women.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Epilepsy; Female; Humans; Parity; Pregnancy | 2013 |
[Stigmata of dysembryogenesis and physical development in children born to mothers with epilepsy].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child Development; Child, Preschool; Developmental Dis | 2011 |
Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy, Generalize | 2013 |
Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Child; Child, Preschool; Developmental Disabil | 2002 |
Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Rel | 2002 |
Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anticonvulsants; Chromosome Aberrations | 2003 |
Successful pregnancy in a patient with hyperoxaluria and combined liver and renal transplant.
Topics: Adult; Epilepsy; Female; Humans; Hyperoxaluria; Infant, Newborn; Kidney Transplantation; Liver Trans | 2003 |
Posterior reversible encephalopathy syndrome (PRES) in critically ill obstetric patients.
Topics: Adult; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Nervous System Diseases; Postpartu | 2003 |
The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months.
Topics: Abortion, Induced; Anticonvulsants; Australia; Carbamazepine; Cohort Studies; Congenital Abnormaliti | 2003 |
[Fetal valproate syndrome].
Topics: Anticonvulsants; Epilepsy; Female; Humans; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complicatio | 2003 |
[Influence of valproic acid (depakine I.V.) on human placenta metabolism--experimental model].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Blood Glucose; Embryo, Mammalian; Embryonic and Fetal | 2003 |
Evidence-based mental health use of anticonvulsants during pregnancy.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Clinical Trials as Topic; Evidence-Based Medicine; Female; | 2003 |
[Fetal valproate syndrome].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Maternal-Fetal Exchange; Pre | 2003 |
Normal intelligence in children with prenatal exposure to carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Child; Child, Preschool; Dose-Response Relationship, Drug; Epilepsy; | 2004 |
Interaction between anticonvulsants and human placental carnitine transporter.
Topics: Acetates; Amines; Aminoisobutyric Acids; Anticonvulsants; Carnitine; Carrier Proteins; Culture Techn | 2004 |
Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study.
Topics: Abnormalities, Multiple; Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Fetal Diseases; Hu | 2004 |
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Child; Cohort Studies; Confoundi | 2004 |
Longer term outcome of children born to mothers with epilepsy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsy; Fema | 2004 |
The longer term outcome of children born to mothers with epilepsy.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition Disorde | 2004 |
Australian pregnancy registry of women taking antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Therapy, Combination; Epilepsy; Female | 2004 |
Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Dose-Response Relationship, Drug; Epilepsy; | 2004 |
Complex cardiac defect with hypoplastic right ventricle in a fetus with valproate exposure.
Topics: Abortion, Induced; Adult; Anticonvulsants; Diagnosis, Differential; Epilepsy; Female; Heart Defects, | 2005 |
What can we say to women of reproductive age with epilepsy?
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; E | 2005 |
Maternal valproate dosage and foetal malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Logistic Models; Pregnancy; | 2005 |
Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes.
Topics: Abnormalities, Drug-Induced; Adolescent; Anthropometry; Anticonvulsants; Carbamazepine; Child; Child | 2006 |
Antiepileptic drug use and birth rate in patients with epilepsy--a population-based cohort study in Finland.
Topics: Adolescent; Adult; Anticonvulsants; Birth Rate; Carbamazepine; Cohort Studies; Epilepsy; Female; Fin | 2006 |
The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children.
Topics: Anticonvulsants; Carbamazepine; Child; Cognition; Education, Special; Epilepsy; Female; Humans; Ment | 2006 |
Plasma vitamin values and antiepileptic therapy: case reports of pregnancy outcomes affected by a neural tube defect.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Folic Acid; Genetic Predisposition to Disease; Homocystein | 2007 |
Observations on juvenile myoclonic epilepsy amongst ethnic Bengalees in West Bengal--an Eastern Indian State.
Topics: Abnormalities, Drug-Induced; Age of Onset; Anticonvulsants; Benzodiazepines; Clobazam; Electroenceph | 2007 |
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Carbamazepine; Cerebral Cortex; Female; Fetus | 2007 |
Phenytoin but not valproate directly affected in vitro trophoblast differentiation.
Topics: Anticonvulsants; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Epilepsy; | 2008 |
The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies.
Topics: Anticonvulsants; Australia; Birth Weight; Epilepsy; Female; Fetus; Humans; Pregnancy; Pregnancy Comp | 2007 |
Congenital gingival hyperplasia in a neonate with foetal valproate syndrome.
Topics: Adult; Anticonvulsants; Apgar Score; Craniofacial Abnormalities; Dose-Response Relationship, Drug; E | 2007 |
Valproic acid during pregnancy.
Topics: Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications; Valproic Acid | 1980 |
Valproic acid and spina bifida.
Topics: Adult; Anencephaly; Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications; S | 1983 |
Spina bifida and in-utero exposure to valproate.
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complications; Spina Bif | 1984 |
Valproate and spina bifida.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Epilepsy; Female; Humans; Middle Aged; Pregnancy; Pr | 1984 |
Spina bifida and sodium valproate.
Topics: Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications; Spina Bifida Occulta; | 1983 |
[Spina bifida caused by valproic acid?].
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complic | 1983 |
Transplacental passage and half-life of sodium valproate in infants born to epileptic mothers.
Topics: Epilepsy; Female; Fetal Blood; Half-Life; Humans; Infant, Newborn; Maternal-Fetal Exchange; Pregnanc | 1983 |
Treatment of epilepsy in women of child-bearing age: patients' opinion of teratogenic potential of valproate.
Topics: Adolescent; Adult; Attitude; Drug Therapy, Combination; Epilepsy; Female; Humans; Infant, Newborn; M | 1983 |
Antiepileptic drugs and teratogenesis. How should patients, doctors and health authorities be counselled?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant, Newbo | 1983 |
[Case of congenital anomalies born to an epileptic woman treated with valproic acid and phenobarbital].
Topics: Abnormalities, Drug-Induced; Ear, External; Epilepsy; Esotropia; Female; Humans; Infant; Phenobarbit | 1983 |
[Is valproic acid teratogenic?].
Topics: Abnormalities, Drug-Induced; Adult; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; Infa | 1983 |
Possible teratogenic effect of valproate during pregnancy.
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Infant, Newborn; Maternal-Fetal Exchange; Pre | 1983 |
[Pharmacotherapy of epilepsy--current problems and controversies].
Topics: Adolescent; Adult; Carbamazepine; Child; Child, Preschool; Epilepsies, Partial; Epilepsy; Epilepsy, | 1983 |
Protein binding of valproic acid in maternal and umbilical cord serum.
Topics: Adolescent; Adult; Blood Proteins; Epilepsy; Female; Fetal Blood; Humans; Pregnancy; Pregnancy Compl | 1984 |
Valproic acid and congenital malformations. A case report.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Epilepsy; Female; Humans; Infant, Newbo | 1984 |
Congenital liver damage after treatment of mother with valproic acid and phenytoin?
Topics: Adult; Epilepsy, Tonic-Clonic; Female; Humans; Infant; Liver; Liver Diseases; Maternal-Fetal Exchang | 1984 |
The fetal valproate syndrome.
Topics: Epilepsy; Face; Female; Heart Defects, Congenital; Humans; Infant, Low Birth Weight; Infant, Newborn | 1984 |
[Use of valproic acid in pregnancy: an indication for prenatal diagnosis of spina bifida].
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complic | 1984 |
[Use of valproic acid by pregnant women with epilepsy and the risk of congenital abnormalities in the child].
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complic | 1984 |
Teratogenicity of valproic acid.
Topics: Abnormalities, Drug-Induced; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications; Se | 1980 |
Teratogenic effects of anticonvulsants.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Carbamazepine; Cleft Palate; Eyelid Diseases; | 1981 |
Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers.
Topics: Abnormalities, Drug-Induced; Aminopyrine; Breath Tests; Epilepsy; Female; Fetal Blood; Half-Life; Hu | 1981 |
Sodium valproate in pregnancy.
Topics: Adult; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complications; Valproic Acid | 1981 |
Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy.
Topics: Adult; Anticonvulsants; Antipyrine; Delivery, Obstetric; Dose-Response Relationship, Drug; Epilepsy; | 1982 |
[Human teratogenicity of valproic acid containing antiepileptic drugs].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complic | 1982 |
Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs.
Topics: Adult; Autistic Disorder; Child, Preschool; Clonazepam; Developmental Disabilities; Epilepsy; Family | 1994 |
Juvenile myoclonic epilepsy.
Topics: Adolescent; Age of Onset; Animals; Anticonvulsants; Child; Circadian Rhythm; Clonazepam; Cricetinae; | 1995 |
Lithium: the present and the future.
Topics: Acute Disease; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Interactions; Female; Huma | 1995 |
Neonatal fibrinogen depletion caused by sodium valproate.
Topics: Afibrinogenemia; Epilepsy; Female; Humans; Infant, Newborn; Male; Maternal-Fetal Exchange; Pregnancy | 1994 |
Aplasia cutis congenita of the scalp in an infant exposed to valproic acid in utero.
Topics: Abnormalities, Drug-Induced; Adult; Causality; Epilepsy; Female; Humans; Infant, Newborn; Male; Preg | 1994 |
Radial ray aplasia in utero: a prenatal finding associated with valproic acid exposure.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Carbamazepine; Epilepsy, Absence; Female; Huma | 1994 |
Pregnancy, epilepsy, management and outcome: a 10-year perspective.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Birth Weight; Carbamazepine; Cohort Studies; Drug Ther | 1993 |
Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero.
Topics: Drug Administration Schedule; Epilepsy; Female; Heart Defects, Congenital; Humans; Infant, Newborn; | 1993 |
Teratogenicity of antiepileptic drugs and drug specific malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug | 1993 |
Preaxial ray reduction defects as part of valproic acid embryofetopathy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Abortion, Therapeutic; Adolescent; Adult; Extr | 1993 |
Vitamins to prevent neural-tube defects.
Topics: Epilepsy; Female; Humans; Neural Tube Defects; Pantothenic Acid; Pregnancy; Pregnancy Complications; | 1993 |
Treating epilepsy--when, with what and by whom?
Topics: Adult; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complications; Seizures; Valproic Acid | 1993 |
Fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Anticonvulsants; Epilepsy; Face; Female; Human | 1995 |
Acute manic episodes in pregnancy.
Topics: Adult; Bipolar Disorder; Chlorpromazine; Comorbidity; Diabetes Mellitus, Type 1; Drug Therapy, Combi | 1996 |
[Embryofetopathy due to valproate: a pathology only little known. Apropos of 4 cases].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child, Preschool; Cleft Lip; Epilepsy; Face; Female; F | 1996 |
Fetal valproate embryopathy in twins: genetic modification of the response to a teratogen.
Topics: Abnormalities, Multiple; Adult; Anticonvulsants; Diseases in Twins; Epilepsy; Female; Humans; Infant | 1996 |
Teratogenic effects of antiepileptic drugs: what do we advise patients?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Patient Advoc | 1997 |
[Prenatal ultrasonographic diagnosis in the epileptic mother on valproic acid. Retrospective study of 161 cases in the central eastern France register of congenital malformations].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; France; Humans; Population Surveilla | 1998 |
Valproate-induced biochemical abnormalities in pregnancy corrected by vitamins: a case report.
Topics: Adult; Anticonvulsants; Epilepsy; Ethosuximide; Female; Humans; Metabolic Diseases; Pantothenic Acid | 1999 |
Status epilepticus during pregnancy. A case report.
Topics: Anticonvulsants; Epilepsies, Myoclonic; Female; Humans; Obstetric Labor Complications; Pregnancy; Pr | 1999 |
Safe use of valproic acid during pregnancy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Neural Tube Defects; Pregnancy; Pregnancy Complica | 1999 |
Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy, Generalized; Female; Folic Acid; Huma | 1999 |
Malformations in offspring of women with epilepsy: a prospective study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Comorbidity; Congenital Abnormalities; | 1999 |
Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate.
Topics: Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsy; Female; Humans; Hypoglycemia; I | 2000 |
Population based, prospective study of the care of women with epilepsy in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Fetal Death; Guidelin | 2000 |
Fetal valproate syndrome and autism: additional evidence of an association.
Topics: Autistic Disorder; Child; Child, Preschool; Developmental Disabilities; Epilepsy; Female; Follow-Up | 2001 |
The teratogenicity of anticonvulsant drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Case-Control Studies; Congenital Abnorm | 2001 |
[Hyperammonia, hypoglycemia and thrombocytopenia in a newborn after materanl treatment with valproate].
Topics: Adult; Ammonia; Anticonvulsants; Female; Humans; Hypoglycemia; Infant, Newborn; Infant, Newborn, Dis | 2001 |
Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Genetic Predisposition to Disease; Gravidity; Humans; Neur | 2001 |
Septo-optic dysplasia as a manifestation of valproic acid embryopathy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adolescent; Antimanic Agents; Child, Preschool | 2001 |
Craniosynostosis and fetal exposure to sodium valproate.
Topics: Anticonvulsants; Child; Child, Preschool; Craniosynostoses; Epilepsy; Female; Fetus; Humans; Infant; | 2001 |
Fatal cardiac malformation in fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Fatal Outcome; Female; Heart Defects, | 2001 |
'Foetal valproate syndrome and autism: additional evidence of an association'.
Topics: Abnormalities, Drug-Induced; Autistic Disorder; Child; Epilepsy, Generalized; Female; Humans; Male; | 2001 |
[Metopic craniosynostosis, probable effect of intrauterine exposure to maternal valproate treatment].
Topics: Abnormalities, Drug-Induced; Craniosynostoses; Diseases in Twins; Epilepsy, Generalized; Female; Hum | 2001 |
Sodium valproate, pregnancy, and neonatal hyperglycinaemia.
Topics: Adult; Epilepsy; Female; Glycine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Pregnancy; Pre | 1979 |
Sodium valproate and pregnancy.
Topics: Adult; Breast Feeding; Epilepsy; Female; Humans; Infant, Newborn; Male; Maternal-Fetal Exchange; Mil | 1979 |
The disposition of valproate and its metabolites in the late first trimester and early second trimester of pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, co-medication, and the presence of spina bifida.
Topics: Amniocentesis; Amniotic Fluid; Drug Therapy, Combination; Epilepsy; Female; Gas Chromatography-Mass | 1992 |
Preaxial polydactyly in the fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Face; Female; Fingers; Humans; Infant, Newborn | 1992 |
Neural tube defects in association with epilepsy and its treatment.
Topics: Epilepsy; Female; Humans; Neural Tube Defects; Pregnancy; Pregnancy Complications; Valproic Acid | 1992 |
Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs.
Topics: Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsy; Female; Humans; Infant; Infant, | 1992 |
The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Fetal Diseases; Humans; Infant; Infant, Newborn; Male; Pre | 1992 |
Antiepileptics and the development of congenital anomalies.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Apgar Score; Birth Weight; Carbamazepine; Epilepsy; Fe | 1992 |
Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cohort Studies; Epilepsy; Female; Humans; Odds | 1992 |
Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Cohort Studies; Drug Prescriptions; Epi | 1992 |
[The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combin | 1991 |
Sodium valproate in pregnancy.
Topics: Epilepsy; Female; Fetal Diseases; Humans; Neural Tube Defects; Pregnancy; Pregnancy Complications; V | 1991 |
[Effects of antiepileptic drugs on delivery and early childhood--comparison among mono-therapies of valproic acid, phenytoin, carbamazepine and phenobarbital].
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Birth Weight; Carbamazepine; Embryonic and Feta | 1991 |
The fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Child, Preschool; Face; Female; Humans; Male; | 1991 |
PIVKA-II (protein induced by vitamin K absence-II) status in newborns exposed to anticonvulsant drugs in utero.
Topics: Adult; Anticonvulsants; Biomarkers; Diazepam; Epilepsy; Factor VII; Factor X; Female; Humans; Infant | 1991 |
On the use of anticonvulsants for manic depression during pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Bipolar Disorder; Carbamazepine; Female; Humans; Infan | 1990 |
Neocerebellar hypoplasia in a neonate following intra-uterine exposure to anticonvulsants.
Topics: Abnormalities, Drug-Induced; Cerebellum; Drug Therapy, Combination; Epilepsy; Female; Humans; Nerve | 1990 |
Use of anticonvulsants for manic depression during pregnancy.
Topics: Bipolar Disorder; Female; Humans; Neural Tube Defects; Pregnancy; Pregnancy Complications; Valproic | 1990 |
[The first case of a child born with fetal valproic acid syndrome in Hungary].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Maternal-Fe | 1989 |
Epilepsy in women of childbearing age.
Topics: Abnormalities, Drug-Induced; Adult; Carbamazepine; Epilepsy; Female; Humans; Pregnancy; Pregnancy Co | 1989 |
[Valproate induced fetopathy and somatic and psychomotor development].
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Fetal Diseases; Humans; Maternal-Fetal Exchange; Preg | 1989 |
Valproate and spina bifida.
Topics: Adult; Epilepsy; Female; Humans; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications; Spina | 1989 |
In-utero exposure to valproate and neural tube defects.
Topics: Anticonvulsants; Epilepsy; Female; Fetus; Humans; Infant, Newborn; Maternal-Fetal Exchange; Neural T | 1986 |
Sodium valproate, pregnancy, and infantile fatal liver failure.
Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Epilepsy; Female; Humans; Infant; Infant, New | 1987 |
Valproate, spina bifida, and birth defect registries.
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complications; Registrie | 1988 |
[Maternal treatment with sodium valproate. An indication for amniocentesis].
Topics: Amniocentesis; Female; Humans; Pregnancy; Pregnancy Complications; Valproic Acid | 1985 |
Enzymatic and morphological response of the thymus to drugs in normal and zinc-deficient pregnant rats and their fetuses.
Topics: Animals; Cell Membrane; Dexamethasone; Ethanol; Female; Fetus; Histocytochemistry; Microscopy, Elect | 1987 |
Effect of treatment with sodium valproate on plasma adrenocorticotropic hormone and cortisol concentrations in pregnancy.
Topics: Adrenocorticotropic Hormone; Adult; Epilepsies, Myoclonic; Female; Fetal Blood; Fetus; Humans; Hydro | 1985 |
Prenatal detection of a neural tube defect after fetal exposure to valproic acid.
Topics: Abortion, Therapeutic; Adolescent; Epilepsy; Female; Fetal Diseases; Humans; Hydrocephalus; Meningom | 1986 |
[Progressive myoclonus epilepsy and pregnancy].
Topics: Adult; Benzodiazepinones; Clonazepam; Drug Therapy, Combination; Electroencephalography; Epilepsies, | 1986 |
Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Epilepsy; Female; Fetus; Growth; Humans; Infant, New | 1986 |
Prescribing in pregnancy.
Topics: Epilepsy; Female; Humans; Neural Tube Defects; Pregnancy; Pregnancy Complications; Valproic Acid | 1987 |
Anticonvulsant drugs in monotherapy. Effect on the fetus.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Fe | 1987 |
The management of epilepsy in women of child-bearing age and the Australian experience of valproate in pregnancy.
Topics: Abnormalities, Drug-Induced; Australia; Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregna | 1987 |
Fetal valproate syndrome: is there a recognisable phenotype?
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Epilepsy, Tonic-Clonic; Female; Humans; Infant | 1987 |
Mono-unsaturated metabolites of valproic acid in epileptic women and their neonates.
Topics: Adult; Epilepsy; Female; Fetus; Humans; Infant, Newborn; Maternal-Fetal Exchange; Placenta; Pregnanc | 1987 |
Congenital abnormalities in two sibs exposed to valproic acid in utero.
Topics: Abnormalities, Drug-Induced; Carbamazepine; Child; Child, Preschool; Epilepsy; Female; Humans; Infan | 1988 |
Effects of pregnancy on seizure threshold and the disposition and efficacy of antiepileptic drugs in the mouse.
Topics: Animals; Anticonvulsants; Carbamazepine; Electroshock; Female; Kinetics; Mice; Phenobarbital; Phenyt | 1985 |
Valproic acid therapy and neural tube defects.
Topics: Abortion, Induced; Adult; Amniocentesis; Female; Genetic Counseling; Humans; Neural Tube Defects; Pr | 1985 |
Effects of pregnancy on antiepileptic drug utilization.
Topics: Anticonvulsants; Biological Availability; Carbamazepine; Epilepsy; Female; Humans; Kinetics; Metabol | 1985 |
Concentration of valproate during pregnancy, in the newborn and in breast milk.
Topics: Adult; Body Weight; Epilepsy; Female; Fetal Blood; Humans; Kinetics; Maternal-Fetal Exchange; Milk, | 1985 |
Maternal epilepsy and birth defects: a case-control study in the Italian Multicentric Registry of Birth Defects (IPIMC).
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Chromosome Aberrations; Chromosome Disorders; Chromoso | 1985 |